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I. INTRODUCTION 
 
Over-activation of both fast, ionotropic and slower metabotropic glutamate 
receptors during acute central nervous system (CNS) insults has been implicated in the 
neuropathophysiology of epilepsy, Alzheimer’s disease, and CNS trauma (Croucher and 
Bradford, 1989); (Lee et al., 2000); (Choi et al., 1987a). Glutamate-mediated 
neurotransmission and excitotoxicity have thus been the defining examples of the duality 
of the signaling mechanisms which serve the nervous system in health, but which often 
become the very mediators of neuronal cell degeneration in disease settings (Lee et al., 
1999). 
Thyrotropin-releasing hormone (TRH) is a well-described neuroendocrine 
hormone in control of thyroid hormone function, although studies have shown that it may 
also serve as an important modulator of CNS function. TRH is known to be part of the 
regulation of the hypothalamic-pituitary-thyroid axis, and also is involved as a 
neuropeptide in the CNS and other neural tissues (Gary et al., 2003); (Nillni and 
Sevarino, 1999). 
Clinically, TRH has shown therapeutic potential against many neurodegenerative 
disorders (Kubek and Garg, 2002) suggesting a close association of TRH with excitatory 
activity. TRH has shown efficacy in affective and cognitive disorders, alcohol 
withdrawal, and in selected neurodegenerative disorders such as intractable epilepsies, 
progressive cerebellar ataxia, and acute neurotrauma (Faden et al., 1982b); (Gary et al., 
2003); (Kubek and Garg, 2002); (Nie et al., 2005); (Nillni and Sevarino, 1999).  
However, the mechanism of the TRH neuroprotective effect has not been completely 
elucidated. 
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One mechanism of protection against excitatory amino acid (EAA)/glutamate-
induced neurotoxicity could include slowing the progression of processes involving the 
glutamatergic second messenger cascade, which may in fact stop the progression of cell 
injury and death in vivo that occur as a result of this cellular signaling (Choi and Mallet, 
1999); (Gary et al., 2003). In addition to the ionotropic glutamate receptors, both 
glutamate and TRH use metabotropic G-protein coupled receptors to initiate their second 
messenger signal transduction cascade. Moreover, group I metabotropic glutamate 
receptors (mGluRs), which induce toxicity, and TRH share identical signal transduction 
cascades, as described in the following sections. 
Receptor downregulation of shared cellular G-protein subunits has been shown as 
a possible mechanism for heterologous receptor desensitization (Drmota et al., 1998); 
(Milligan and Green, 1997). This concept will be explored in subsequent sections. 
Summaries of the role of glutamate as a neurotransmitter and its association with 
neurological disorders are presented first, followed by a description of the hippocampus, 
focusing on TRH and glutamate receptor distribution. TRH biosynthesis, inactivation, 
and receptor distribution are briefly described, followed by a summary of the role of TRH 
in neuroprotection. Lastly, since the focus for this work involves the modulation of 
glutamate excitotoxicity by TRH, our current understanding of heterologous receptor 
desensitization is presented. 
 
A. Glutamate as a Neurotransmitter 
Watkins notes in his 2006 review that in the late 1950s and early 1960s, the first 
evidence that the amino acid glutamate may serve as a neurotransmitter in the central 
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nervous system (CNS) came when it and other acidic amino acids were found to serve an 
excitatory function in many types of central nervous system neurons. An early indicator 
of the role of glutamate in electrophysiological processes was the observation in the 
1950s that glutamate injection into the brain or carotid arteries produced convulsions. It 
was thus speculated that glutamate was a transmitter in the mammalian CNS (Watkins 
and Jane, 2006). These findings spurred a massive research effort that eventually 
established glutamate as the primary excitatory neurotransmitter in the vertebrate CNS. 
Glutamatergic synaptic transmission was shown to involve the opening of ligand-
gated cation channels via ionotropic glutamate receptors, (iGluRs) that were identified as 
NMDA, AMPA, and kainate receptor subtypes. Glutamate, it is now known, plays a 
major role both as a fast excitatory transmitter, and it has been demonstrated that most 
central neuronal circuits involve glutamatergic neurotransmission at some level (Watkins, 
2000); (Conn, 2003). 
Until the mid-1980s, the actions of glutamate in the mammalian brain were 
thought to be mediated exclusively by activation of the glutamate-gated cation channels, 
which mediate the vast majority of fast excitatory synaptic transmissions in the 
mammalian brain. Fast synaptic transmission through networks of neurons can be 
modulated by activation of receptors coupled to second messenger systems through GTP-
binding proteins. In a network of neurons connected by glutamatergic synapses, for 
example, it was generally held that glutamate would elicit fast synaptic responses by 
activating members of the ionotropic glutamate receptor family. Neuromodulators from 
extrinsic afferents (e.g., acetylcholine, serotonin, and norepinephrine) could then 
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modulate transmission through the network of glutamatergic neurons by activating GTP-
binding protein-linked receptors and second messenger systems (Watkins and Jane, 
2006). 
Activation of G-protein coupled receptors (GPCRs) through extrinsic 
neuromodulatory pathways can elicit a wide variety of effects in glutamatergic circuits, 
including increases or decreases in neurotransmitter release, changes in neuronal 
excitability, and changes in rate and patterns of action potential firing, among other 
changes. These modulatory effects can dramatically increase or decrease net transmission 
of information through a neuronal circuit (Conn, 2003). 
Substances are defined as neurotransmitters if they are substances released at a 
synapse by one neuron and affect another cell (effector) in a specific functional manner, 
and therefore they must have a receptor. Glutamate has been shown to depolarize CNS 
neurons, and systemic administration of glutamate to animals of various species causes 
acute degeneration of neurons in the retina or several areas of the brain that lack blood-
brain barriers (Olney et al., 1971); (Olney and Sharpe, 1969). 
 Of the amino acids in the adult CNS, L-glutamate and L-aspartate are the most 
likely candidates for neurotransmitter action at excitatory amino acid receptors, and are 
used by some of the most widely distributed neuronal types. Both are present in high 
concentrations in the CNS, and are released in a Ca2+-dependent manner upon electrical 
stimulation in vitro. Both have powerful excitatory effects on neurons when 
iontophoresed in vivo, and high-affinity uptake systems are located on nerve terminals of 
many neuronal pathways (Watkins, 2000); (Watkins and Jane, 2006). 
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Additionally, both glutamate and aspartate are acidic amino acid 
neurotransmitters, which re-enter the cell by a transporter driven by the high extracellular 
concentrations of sodium (Na+) and the high intracellular concentrations of potassium 
(K+). Sodium enters the cell along with the amino acids, and potassium leaves the cell via 
a classic antiport mechanism. Thus, glutamate/aspartate entry is indirectly powered by 
the ATP-driven Na+-K+-ase (sodium pump), which creates the high ion concentration 
gradients.  Selective binding sites can be demonstrated by both autoradiographic and 
pharmacological techniques in vitro. Notably, glutamate is the only L-amino acid that has 
been shown to activate mGluRs (Frauli et al., 2006). 
The unequivocal identification of glutamate and aspartate as neurotransmitters 
was hampered by their involvement in many other functions. For example, glutamate is 
incorporated into proteins; is involved in fatty acid synthesis; contributes to the regulation 
of ammonia levels and the control of osmotic and anion balance; and serves as a 
precursor for GABA and various Krebs cycle intermediates. Not surprisingly, then, 
glutamate is the most abundant amino acid in the CNS, with a concentration almost six 
times that of the principal inhibitory neurotransmitter, GABA. The transmitter pool of 
glutamate may constitute approximately thirty percent of the total glutamate 
concentration in the CNS (Watkins, 2000); (Watkins and Jane, 2006). 
Glutamate and aspartate are potent neuroexcitants, and excess excitatory amino 
acid activity is suspected in the pathophysiology of many CNS disorders, including the 
neurodegenerative disorders noted previously (Choi et al., 1987); (Olney et al., 1986a). 
Historically, the evidence that glutamate and aspartate function as neurotransmitters has 
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come from the observation that at low concentrations both amino acids function to excite 
most cells in the CNS. Under physiological conditions the major role of synaptically 
released glutamate is to interact with receptors on adjacent cells. Receptor activation 
opens post-synaptic cation channels, which depolarizes the post-synaptic membrane and 
increases the likelihood that a post-synaptic cell will fire an action potential (Schoepp et 
al., 1990b). 
Glutamate and aspartate physiological studies have revealed that their interactions 
with receptors are complex, and several subtypes of glutamate receptors are known to 
exist throughout the CNS. In functional terms, ionotropic glutamate receptors are 
classified as AMPA- or NMDA-preferring. Both classes are present on most neurons of 
the CNS, with a few notable exceptions. There is evidence to suggest that AMPA and 
NMDA receptors are clustered together within the same postsynaptic densities on many 
cell types. This close apposition results in the simultaneous activation of these receptors. 
The integration of current flow through the two-receptor systems endows the cell with a 
powerful means of regulating neuronal excitation (Olney 2000); (Watkins, 2006). 
 
1.  Biosynthesis of Glutamate 
 
Glutamate is synthesized and stored within the synaptic endings of the nerve 
terminal.  Glutamate and aspartate are nonessential amino acids that do not cross the 
blood-brain barrier; therefore, they are not supplied to the brain by the circulation. 
Instead, they are synthesized from glucose and a variety of other precursors. Synthetic 
and metabolic enzymes for glutamate and aspartate have been localized to the two main 
compartments of the brain, neurons and glial cells. Both the synthesis and metabolism of 
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glutamate and aspartate are more dependent on the interaction between the nerve 
terminals and the glial cells than are either the synthesis or metabolism of other groups of 
neurotransmitters (Watkins and Jane, 2006); (Dingledine, 1983). 
Glutamic acid is in a metabolic pool with α-ketoglutaric acid and glutamine. 
Glutamate is released from nerve terminals and, to a large extent, is taken up into glial 
cells where it is converted to glutamine. Glutamine is believed to be cycled back to the 
nerve terminal, where it participates in the replenishment of the transmitter pool of 
glutamate and GABA.  Synthesis of transmitter pools of glutamate is likely to involve 
two major synthetic pathways. In one pathway, the conversion of glutamine to glutamate 
involves the enzymatic action of glutaminase within the mitochondrial compartment 
(Watkins and Jane, 2006). 
The second pathway involves glutamate formation by a process of transamination, 
as follows. Newly-synthesized glutamate is packaged and stored in high concentration 
within synaptic vesicles. After release of glutamate from the nerve terminal into the 
synaptic cleft, it is taken up into glial cells and converted into glutamine, which itself is 
then cycled back to the nerve terminal, where it participates in the replenishment of 
transmitter stores of glutamate (Dingledine, 1983). 
Thus, glucose and glutamine are the precursors of glutamate, which is an essential 
component of cellular metabolism. Ingested proteins are broken down by digestion into 
amino acids, which are then degraded via transamination, in which the amino group of an 
amino acid is transferred to an α-ketoacid, typically catalyzed by a transaminase. 
Notably, α-ketoglutarate, an α-ketoacid, is an intermediate in the citric acid cycle 
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(Krebs’s Cycle), which forms glutamate as the product of transamination (Watkins and 
Jane, 2006). 
Glutamate also plays an important role in the body's disposal of excess or waste 
nitrogen. Glutamate undergoes deamination, an oxidative reaction catalyzed by glutamate 
dehydrogenase, resulting in α-ketoglutarate and ammonia, which is then excreted 
predominantly as urea (Watkins, 2000); (Dingledine, 1983). 
Another area of current research involves vesicular glutamate transporters 
(VGLUTs). Danik and colleagues recently reported their work with vesicular glutamate 
transporters, describing the VGLUT1 and VGLUT2 distribution both anatomically and 
temporally during brain development.  They found, using RT-PCR, that VGLUT1 and 
VGLUT2 mRNAs were co-expressed in most of the sampled neurons harvested from rat 
hippocampus, cortex, and cerebellum at postnatal day P14, but not at P60. Similarly, 
changes in the concentrations of both VGLUT1 and VGLUT2 mRNA were found to 
occur in these and other brain areas between P14 and P60, via semi-quantitative RT-PCR 
as well as via quantitative ribonuclease protection assays (Danik et al., 2005). 
Danik found that VGLUT1 and VGLUT2 co-expression in the hippocampal 
formation is supported further by in situ hybridization data, which indicated that almost 
100% of the sampled cells from the hippocampal CA1 – CA3 pyramidal and granule cell 
layers were highly positive for both transcripts until P14 (Danik et al., 2005). 
 
2. Inactivation of Glutamate 
Glutamate stimulation is terminated by a chloride-independent membrane 
transport, which reabsorbs glutamate and aspartate across the pre-synaptic membrane. 
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Glutamate released into synapses is either reabsorbed directly into neurons by the ion-
exchange transport system, or is removed by astrocytes (glial cells), which convert the 
glutamate into glutamine (a molecule which cannot cause excitotoxicity). Both the pre- 
and post-synaptic neurons at glutamic acid synapses have glutamic acid-reuptake 
systems, which quickly lower glutamic acid concentration (Watkins and Jane, 2006). 
The acceptance of L-glutamate as a neurotransmitter required that a means to 
terminate the excitatory signal be identified. Early studies detailing the presence of 
uptake systems capable of transporting glutamate and aspartate into neurons and glia 
represented a key step in the overall task of demonstrating that L-glutamate was an 
endogenous excitatory neurotransmitter. Rapid transport out of the synaptic cleft 
provided a plausible mechanism, particularly in the absence of a classic degradative 
enzyme (Bridges and Esslinger, 2005). This transport activity also served as one of the 
first biochemical markers of excitatory synapses (Cotman et al., 1981). Two of the 
properties that emerged from these studies that clearly distinguished the uptake of L-
glutamate into CNS preparations were a high-affinity for substrate as well as a 
requirement for sodium (Logan and Snyder, 1972); (Bridges and Esslinger, 2005). 
Early indications that glutamate uptake in the CNS was not mediated by a single 
homogenous system were primarily identified via comparative pharmacological studies, 
where the potency of inhibitors were observed to vary among CNS preparations (Roberts 
and Watkins, 1975); (Balcar et al., 1978); (Schousboe and Waagepetersen, 2006); 
(Takamoto et al., 2002); (Robinson et al., 1993). This issue was resolved when three 
different high-affinity, sodium-dependent glutamate transporters were cloned and 
expressed: GLAST (Storck et al., 1992) and GLT-1 (Pines et al., 1992) from rat brain and 
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EAAC1 (Kanai and Hediger, 1992) from rabbit intestine. Isolation of the homologous 
transporters from human brain occurred two years later. These were referred to as 
excitatory amino acid transporters (EAAT) 1, 2, and 3, respectively (Arriza et al., 1994). 
Subsequently, screens of cDNA libraries from human cerebellum and retina have resulted 
in the isolation of EAAT4 (Fairman et al., 1995) and EAAT5 (Arriza et al., 1997), 
respectively. Sequence comparisons among the 5 EAATs indicated that about 50–60% 
homology exists among the subtypes (Seal and Amara, 1999); (Bridges and Esslinger, 
2005). 
 
3.  Receptor Distribution in the Hippocampus 
 
The glutamate receptor family is comprised of two major subfamilies, and within 
these subfamilies are additional categories and subcategories. Glutamate binds to two 
types of receptors in the synaptic cleft: metabotropic and ionotropic. Notably, 
metabotropic receptors (mGluRs) do not form an ion channel pore; rather, they are 
indirectly linked on the plasma membrane with ion-channels through second messenger 
systems, as described below (Pin and Duvoisin, 1995); (Conn and Pin, 1997); (Schoepp 
and Conn, 1993). 
Direct evidence for the existence of glutamate receptors directly coupled to 
second messenger systems via G-proteins began to appear in the mid-1980s, when 
Sladezeck and colleagues were the first to report that glutamate analogues could activate 
receptors coupled to activation of phosphoinositide hydrolysis in striatal neurons 
(Sladeczek et al., 1985).  Nicoletti and coworkers then demonstrated a similar response in 
hippocampal slices (Nicoletti et al., 1986b) and cerebellar granule cells, (Nicoletti et al., 
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1986a). Sugiyama and colleagues reported in 1987 that expression of rat brain mRNA in 
Xenopus frog oocytes led to the expression of a novel glutamate receptor that is coupled 
to activation of phosphoinositide hydrolysis (Sugiyama et al., 1987); (Conn, 2003). 
At least eight receptor subtypes have now been identified within the metabotropic 
family, some of which achieve signal transduction through G-protein coupling to a 
phosphoinositide second messenger system, as described below, and others to an 
adenylate cyclase system (Schoepp et al., 1994). Metabotropic glutamate receptors 
(mGluRs) are seven transmembrane G-protein coupled receptors which are found in pre- 
and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral 
cortex, as well as other parts of the brain and peripheral tissues, and are implicated in the 
regulation of many physiological and pathological processes in the CNS, including 
synaptic plasticity, learning and memory, motor coordination, pain transmission, and 
neurodegeneration. 
These mGluR subtypes are classified into three major groups on the basis of 
sequence homologies, coupling to second messenger systems, and selectivities for 
various agonists (Conn and Pin, 1997). Group I mGluRs, which include mGluR1 and 
mGluR5, couple primarily to Gα and increases in phosphoinositide hydrolysis. Group II 
mGluRs (mGlu2 and mGlu3), and group III mGluRs (mGlu4, 6, 7, and 8) couple to Gi/o 
and associated effector pathways such as inhibition of adenylyl cyclase (Conn, 2003). 
This second messenger cascade of the mGluRs is important when one considers the 
potential of downregulating the heterotrimeric G-proteins through the use of substances, 
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such as TRH, which use the same second messenger cascade, namely Gα, as will be 
described. 
The ionotropic receptors, originally identified by Watkins (Watkins et al., 1990),  
are N-Methyl-D-Aspartate (NMDA) and non-NMDA (AMPA and kainate, KA)  
receptors. NMDA receptors are most densely concentrated in the cerebral cortex 
(hippocampus, especially the CA1 region), amygdala, and basal ganglia. They are 
particularly vulnerable to glutamate excitotoxicity; i.e., damaging effects due to excessive 
excitatory neurotransmitter release. The mRNAs encoding NMDA receptor subunits are 
differentially distributed (Kew and Kemp, 2005); (Watkins and Jane, 2006). 
The distribution of gluatamate receptors within the hippocampus specifically is 
described in a subsequent section. 
 
4. Receptor Physiology 
 
Neurophysiologically, glutamate acts by binding to and activating a number of 
Glu receptors at the synaptic level, and controls either the fast-acting ionotropic channels 
or the longer-acting metabotropic second messenger-mediated events (Conn and Pin, 
1997); (Pin and Duvoisin, 1995); (Schoepp et al., 1999). 
 Regarding the fast-acting ionotropic glutamate receptors, it should be noted that 
NMDA is not naturally found in biological systems, but it binds specifically to the 
ionotropic NMDA glutamate receptor with higher specificity than glutamate. The NMDA 
receptor is actually the only known receptor that is regulated both by a ligand (glutamate) 
and by voltage. Five binding sites have been discovered, which regulate NMDA receptor 
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activity, including sites for (1) glutamate (2) glycine (3) magnesium (4) zinc and (5) a site 
that binds the hallucinogenic substance phencyclidine (PCP).  
Conversely, the delayed process has been studied primarily in cerebrocortical 
neuronal cultures, and has been monitored primarily by biochemical measurement of 
lactic dehydrogenase (LDH) release as an indicator of cellular membrane damage. This 
has been described as a calcium-dependent and NMDA receptor-mediated process, which 
leads to cell death (confirmed via LDH release) in the 16-24 hr time interval. Romano 
adapted the chick embryonic retina model to allow incubation for up to 24 hrs and 
employed both LDH analysis and histological analysis to monitor cell death (Romano et 
al., 1995a); (Romano et al., 1995b). 
The results of the study by Romano did not support the concept of a delayed cell 
death process that is separate and distinct from excitotoxic cell death. Rather, by 
morphological analysis, the cells show signs of acute but quite advanced degeneration 
within two hours after exposure to an excitotoxic agonist, but release of LDH is a slowly 
evolving phenomenon that occurs on a delayed basis primarily in the 16-24 hr interval 
after the degenerating neurons have shown morphological signs of advanced deterioration 
for many hours (Chen et al., 1999); (Olney et al., 2002). 
The potential interaction between group I mGluRs and NMDA receptors in the 
mediation of post-traumatic neuronal death was studied using an in vitro trauma model. 
Treatment with group I mGluR antagonists provided significant neuroprotection either in 
the presence or absence of an NMDA receptor antagonist. Conversely, treatment with 
only a group I mGluR agonist significantly increased the amount of damage; and this 
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damage was significantly, but incompletely, reduced in the presence of an NMDA 
receptor antagonist. It was thus shown that the effects of group I mGluR activation on 
post-traumatic cell death are mediated only in part through NMDA receptor modulation, 
and suggested at the time that group I mGluR antagonists may have therapeutic potential 
(Mukhin et al., 1997). 
Glutamate is involved in many important neurological functions, but this 
discussion will concentrate on its role in excitotoxicty, and further develop that role 
through the experiments, which were conducted in cell, slice, and neuronal systems. The 
major inhibitory and excitatory neurotransmitters in the mammalian CNS are GABA and 
glutamate, respectively. Schoepp states that the balance of excitation/inhibition within 
neuronal circuits is highly dependent on postsynaptic activation of ionotropic receptors 
for these ligands (GABAA or AMPA/kainate/NMDA receptors). 
 The related proteins, GABAB and mGluRs, function in nervous tissue to 
recognize these ligands, but they serve a more modulatory role in the control of 
excitation/inhibition (Schoepp, 2001). Glutamate is the transmitter of the vast majority of 
the fast excitatory synapses in the mammalian CNS and plays an important role in a wide 
variety of CNS functions (Hollmann and Heinemann, 1994). 
The search for mGluR-related cDNA resulted in the isolation of seven other genes 
and several splice variants that encode mGluRs (Tanabe et al., 1992); (Pin et al., 1992); 
(Nakajima et al., 1993); (Okamoto et al., 1994); (Saugstad et al., 1997); (Joly et al., 
1995); (Minakami et al., 1994); (Duvoisin et al., 1995); (Iversen et al., 1994); (Laurie et 
al., 1996). These receptors are named mGluR1 through mGluR8 (Conn and Pin, 1997). 
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These eight different types of mGluRs are divided into groups I, II, and III. 
Metabotropic glutamate receptors (mGluR1-8) function to modulate brain excitability via 
pre-synaptic, post-synaptic, and glial mechanisms, and each consists of G-protein 
coupled receptors (GPCRs). There is reportedly an approximately 70% sequence 
homology within each mGluR receptor group; whereas, between the subgroups there is 
lesser (40%) homology (Schoepp, 2001).  
In general, it is believed that mGlu receptors have evolved as modulatory 
mechanisms to control CNS excitability. Group I mGlu receptors include mGluR1 and 
mGluR5, which when expressed are coupled via Gq to phospholipase-C. Group II 
(mGluR2 and mGluR3) and Group III (mGluR4, 6, 7, and 8) receptors are coupled to Gi 
and inhibit stimulated cAMP formation when expressed in cell lines (Schoepp, 2001).  
The mGluRs in group I, including mGluR1 and mGluR5, are stimulated most 
strongly by the excitatory amino acid analog L-quisqualate. They are present 
presynaptically, postsynaptically, and also on glia. Stimulating these receptors causes an 
associated phospholipase-C (PLC) molecule to hydrolyze phosphoinositide phospholipids 
(IP3). 
Group I metabotropic receptors have a variety of means whereby they propogate 
glutamate excitotoxicty, extending over more time than ionotropic events, thus resulting 
in more serious damage than that caused by the activation of the ionotropic receptors (Pin 
and Duvoisin, 1995). Additionally, there is biochemical and electrophysiological 
evidence that groups I, II, and III play a role in the modulation of glutamate release 
(Anwyl, 1999); (Cartmell and Schoepp, 2000). 
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The group I mGlu receptors are primarily postsynaptic, functioning to enhance 
cellular excitability via interactions with other postsynaptic processes, such as ionotropic 
receptors and ion channels (Bordi and Ugolini, 1999); (Schoepp, 2001). Some 
biochemical evidence exists for a presynaptic role for the mGlu receptors, but group II 
and group III mGlu receptor subtypes predominate on presynaptic sites, where they 
regulate glutamate release (Schoepp, 2001). 
According to Conn and Pin, the discovery of mGluRs dramatically altered the 
traditional view of glutamatergic neurotransmission, since activation of mGluRs can 
modulate activity in glutamatergic circuits in a manner previously associated only with 
neuromodulators from nonglutamatergic afferents. Unlike receptors for monoamines and 
other neuromodulators, however, the mGluRs are believed to provide a mechanism by 
which glutamate modulates synaptic activity at the same site at which it elicits fast 
synaptic responses (Conn and Pin, 1997). 
Additionally, mGluRs have the potential to participate in a wide variety of 
functions of the CNS, due to the widespread distribution of glutamatergic synapses. 
Finally, the wide diversity and heterogeneous distribution of mGluR subtypes provide an 
opportunity for developing pharmacologic agents that selectively interact with mGluRs 
involved in only one or a limited number of CNS functions. Thus, it is widely believed 
that gaining a detailed understanding of the specific roles of mGluRs will probably have a 
major impact on development of novel treatment strategies for a variety of neurologic 
disorders (Conn and Pin, 1997). 
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The first mGluR cDNA was cloned independently by two groups that used the 
same functional expression assay and is now generally named mGluR1a (Masu et al., 
1991); (Houamed et al., 1991). Its deduced amino acid sequence revealed that this 
receptor shares no sequence homology with any other G-protein coupled receptor 
(GPCR), which suggests that it could be a member of a new receptor gene family. 
Pharmacologic studies suggested that several G-protein coupled glutamate receptors 
existed (Schoepp et al., 1990a). 
 
B. Neurological Disorders Associated with Glutamate Toxicity 
Glutamate and its structurally related ligands, in addition to their powerful 
excitatory effects at glutamate receptors, are potent neurotoxins. Glutamate and other 
amino acids were first recognized as neurotoxic agents in the 1970s, when they were 
given orally to immature animals. Acute neurodegeneration was observed in those areas 
not well protected by the blood-brain barrier, notably the arcuate nucleus of the 
hypothalamus. 
Glutamate and specific excitatory amino acid (EAA) analogs cause acute neuronal 
degeneration by excessive stimulation of postsynaptic EAA receptors through which 
glutamate functions physiologically as a transmitter (Olney, 1989); (Olney, 2003). It is 
often maintained that calcium influx or intracellular calcium mobilization may be the 
single most important factor responsible for triggering the cascade of pathophysiological 
events that lead to excitotoxic cell death (Olney et al., 1999); (Kew and Kemp, 2005). 
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Based on early in vitro studies, two separate forms of excitotoxic cell death have 
been identified, an acute form and a delayed form. Acute excitotoxic cell death has been 
described as occurring within minutes or a few hours, and is associated with uptake of 
sodium, chloride, and water, resulting in rapid swelling of the neuron with cell death 
occurring by lysis, studied primarily by morphological methods in isolated chick embryo 
retinas (Olney, 1982). 
Choi and colleagues in the late 1980s demonstrated the ionic dependence of 
glutamate toxicity, demonstrating that morphological changes occur in neuronal culture 
after exposure to toxic glutamate, separated into two components. The first component is 
marked by neuronal swelling, occurs early, and is dependent on extracellular chloride and 
sodium ions. The second component, which occurs later, is distinguished by neuronal 
disintegration, and is dependent on extracellular calcium. 
Choi stated that, while either component could produce neuronal injury, the 
calcium-dependent mechanism predominated at exposure to lower gluatamate levels 
(Choi, 1987). Choi demonstrated a dose-dependent effect of glutamate in cortical cell 
cultures, using micromolar concentrations, which were less than 1% of the millimolar 
concentrations described more than fifty years ago as present normally in whole cortex 
(Waelsch, 1951); (Choi et al., 1987). 
The mechanisms of neurodegeneration are divergent and activation of most 
classes of glutamate receptor has been implicated. Neurodegeneration following an 
ischemic insult may involve mechanisms resembling a pathological exaggeration of LTP-
type phenomena; i.e., the neuronal insult results partially from AMPA receptor activation 
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with simultaneous NMDA receptor activation and Ca2+ influx. A close correlation exists 
between neurotoxic potency and affinity of glutamate receptors for a range of agonists. 
Thus, the more able a compound is to depolarize neurons, the greater the likelihood of 
that agent causing neuronal toxicity (Allen et al., 1999); (Simon et al., 1984). 
Many acute CNS injuries, by definition, involve an excitotoxic mechanism, since 
excitotoxicity is of primary significance in triggering the cell death process. It is the 
classical type of excitotoxic mechanism that is believed to be involved in acute CNS 
injury syndromes, and excitotoxins of both exogenous and endogenous origin have been 
implicated (Olney, 2002). Excitotoxicity is a phenomenon typically encountered in 
neurons following a stimulation that exceeds the physiologic range with respect to 
duration or intensity. Typical excitotoxic mediators are acetylcholine or, most 
importantly in the CNS, glutamate. 
 Many chronic neurodegenerative diseases also have been found to have an 
excitotoxic component (Leist et al., 1999); (Choi, 1992); (Meldrum and Garthwaite, 
1990). Additionally, a causal contribution of excitotoxicity to neuronal damage has been 
established in stroke or head trauma (Lipton and Nicotera, 1998); (Tamargo et al., 1993), 
as well as in acute poisoning phenomena, such as exposure to carbon monoxide (Ishimaru 
et al., 1999); (Olney et al., 2000); (Koliatsos et al., 2004). 
Generally, excitotoxicity is induced by conditions favoring glutamate 
accumulation in the extracellular space, and it is enhanced by conditions (such as energy 
depletion) that hinder cellular protective mechanisms (Novelli and Tasker, 2000). Typical 
conditions leading to increased extracellular glutamate concentrations (Bullock et al., 
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1995); (Rothman, 1900); (Drejer et al., 1985) are depolarization of neurons, energy 
depletion due to hypoglycemia or hypoxia (O'Dowd et al., 2000); (Wieloch et al., 1984), 
or defects in the glutamate reuptake systems (Volterra, 1994). 
A number of major acute CNS injury syndromes, including those associated with 
stroke, hypoglycemia, and status epilepticus, are believed to be triggered by excessive 
activation of glutamate receptors by endogenous excitotoxins, primarily glutamate, but 
probably also aspartate, and possibly sulfur-containing amino acids, thus called excitatory 
amino acid (EAA) toxicity. Excessive release and/or impaired uptake of endogenous 
excitotoxins occur in each of these conditions that lead to an extracellular accumulation 
of these toxins, and to acute degeneration of neurons (Olney, 1969); (Olney et al., 1971); 
(Lucas et al., 1985). 
Thus, excess glutamate triggers excitotoxicity, causing neuronal damage and 
eventual cell death, particularly when NMDA receptors are activated. This may be due to 
high intracellular Ca2+ exceeding storage capacity and damaging mitochondria, leading to 
apoptosis, or to Glu/Ca2+-mediated promotion of transcription factors for pro-apoptotic 
genes, or to downregulation of transcription factors for anti-apoptotic genes. This 
contribution of synaptic activity to neurotoxicity, the release of glutamate and receptor 
stimulation on membranes post-synaptically, was noted by direct observations, which 
showed that glutamate is neurotoxic in vivo when injected directly (Olney, 1969); (Olney 
et al., 1971); (Lucas et al., 1985). 
Inhibition of the neurotransmission by Mg2+ or glutamate antagonists was found 
to protect neurons from hypoxic damage (Rothman and Olney, 1995), and electrically 
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stimulating neurons in the hippocampus stimulated glutamate-induced increases of 
calcium concentrations within the same cell (Tong et al., 1989). Thus, there appears to be 
a very close reciprocal relationship between increased extracellular glutamate 
concentrations and increased calcium concentration, which may result in neuronal death 
under excitotoxic conditions (Koliatsos et al., 2006). 
The initial thought that calcium may be excitotoxic dates back to Fleckenstein’s 
suggestion in 1968 that excessive entry of calcium into cardiomyocytes may be the 
underlying mechanism of cardiac pathology following ischemia (Fleckenstein-Grun et 
al., 1992). Since the 1980s, the relationship between calcium and cell death has been 
examined intensively, especially in hepatocytes, the kidney, and the brain (Nicotera et al., 
1986); (Nicotera et al., 2000); (Nicotera and Leist, 1997); (Trump et al., 1997); (Trump 
and Berezesky, 1996); (Siesjo, 1989); (Siesjo et al., 1989). The key role of calcium in 
excitotoxicity is suggested by three different lines of evidence (Siesjo, 1989); (Dubinsky 
and Oxford, 1985); (Choi, 1994). 
First, there is an obvious increase in calcium concentration both in in vivo and in 
vitro models of excitotoxic cell death, observed in ischemic brain (Simon et al., 1984b); 
(Simon et al., 1984a) or in brain slices exposed to NMDA receptor agonists or anoxia 
(Meldrum and Garthwaite, 1990b); (Kass and Lipton, 1986). Also, glutamate-stimulated 
calcium influx has been shown directly in cultured neurons (Bruno et al., 1998), and 
increased calcium has been detected repeatedly after NMDA receptor stimulation, using 
fluorescent probes. In vivo microelectrode measurements have demonstrated an 80-90% 
 
 
22 
decline of extracellular calcium during ischemia, with a corresponding increase of 
intracellular calcium (Kristian et al., 1993); (Kristian and Siesjo, 1998). 
Secondly, decreasing calcium entry into the neuron by removal of extracellular 
calcium (Choi and Hartley, 1993); (Hartley and Choi, 1989); (Gabellini et al., 1994); 
(Meldrum and Garthwaite, 1990); (Rothman and Olney, 1995), depletion of NMDA 
receptors, pharmacological inhibition of glutamate receptor subtypes or of VDCCs 
(Sucher et al., 1991b); (Sucher et al., 1991a) prevented death in many attempts at 
excitotoxicity (Koliatsos et al., 1993). 
Third, prevention of neurotoxicity by the inhibition of calcium-dependent 
downstream effects most strongly supports a causal role for calcium in neurotoxicity. 
Intracellular calcium chelators have been found to protect against both ischemic damage 
in vivo and excitotoxic neuronal damage in vitro (Tymianski et al., 1993); (Tymianski et 
al., 1994). 
Furthermore, cultured neurons are protected against excitatory amino acid toxicity 
by inhibiting effectors of calcium toxicity such as calmodulin inhibition (Marcaida et al., 
1997); (Marcaida et al., 1996). 
 
1.  Dementias 
Glutamate overstimulation occurs as part of the ischemic cascade, and has been 
associated with dementias, including Alzheimer’s disease. 
Alzheimer’s disease is a neurodegenerative disease with poorly defined 
pathogenic mechanisms. The actions of amyloid-beta (Aß) peptides derived from 
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amyloid precursor proteins (APP) (Mattson, 2006) have been implicated as a cause of 
neuropathological changes. The neurodegeneration observed at autopsy shows apoptotic 
features. Apoptosis is also evoked in vitro by exposure of neuronal cultures to Aß 
(Forloni et al., 1989). The mechanism of Aß toxicity in vitro may involve excessive 
calcium entry into cells. Antigenic changes of cytoskeletal elements typical of 
Alzheimer’s Disease are mimicked by excessive calcium influx into cultured 
hippocampal neurons (Mattson, 2006) and blocking receptor-mediated calcium entry 
prevents Aß toxicity. 
Additionally, Aß-induced disturbances of calcium homeostasis in hippocampal 
neurons is corrected by pretreatment of those cultures with various peptide mediators 
such as fibroblast growth factor (Mattson, 2006) or tumor necrosis factor (Leist et al., 
1997); (Leist and Nicotera, 1998b). An hypothesis by Olney and colleagues explains 
neurodegeneration in Alzheimer’s disease. This hypothesis posits an interaction between 
genetic factors (unfavorable ApoE genotype and Aß-linked genetic mutations) and a form 
of excitotoxicity that occurs spontaneously in the brain under conditions in which 
ionotropic NMDA glutamate receptors are blocked or impaired (Olney et al., 1997). 
 
2. Affective Disorders and Schizophrenia 
Many recent studies have indicated that modulating the glutamatergic system may 
be an efficient method of achieving an antidepressant effect. Palucha and colleagues 
presented data suggesting that mGluRs, since they are involved with long lasting 
modulatory effects on glutamatergic neurotransmission, are a potential target for the 
development of drugs which may be useful in the treatment of several CNS disorders, 
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including depression and anxiety. Palucha and Pilc note that the mGluR5 antagonists and 
group II mGluR antagonists seem to be the most promising compounds, with potential 
antidepressant-like activity in rodents. They do note that the efficacy of mGluR ligands in 
the clinical setting, however, is still an unanswered question (Palucha, 2006); (Palucha 
and Pilc, 2002); (Palucha and Pilc, 2005). 
Wieronska and colleagues have shown that the level of mGluRs in rat brains after 
chronic mild stress was increased in the CA1 and decreased in the CA3 region of the 
hippocampus, via Western blotting assays for the level of the mGluR5 protein. Their 
results indicated that mGluR5 may be involved with the mechanism of depression 
(Wieronska et al., 2001). 
Recent research suggests a combined glutamate/dopamine hypothesis to explain 
the pathophysiology of schizophrenia. This hypothesis, like the hypothesis pertaining to 
Alzheimer’s disease, describes NMDA glutamate receptor hypofunction as a key 
mechanism. 
An integrative model that has also been addressed is the glutamate receptor 
dysfunction model of schizophrenia (Olney et al., 1999). It should be noted that a 
psychosis similar to schizophrenia is induced by phencyclidine (PCP), a non-competitive 
NMDA receptor blocker (Arnold et al., 1973) which causes hallucinations and delusions, 
as well as an associated apathetic state and a formal thought disorder, which are both 
distinctive schizophrenic features. Interestingly, ketamine, an anesthetic agent that binds 
to the PCP site of the NMDA receptor, rarely induces psychosis in children, while 
psychosis occurs upon emergence from anesthesia in many young and middle-aged 
adults. This age dependency of the response to glutamate antagonists is also seen in rats, 
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which become susceptible to the neurotoxic effects of NMDA antagonists between 
puberty and adulthood (Arnold, 1999). 
The precise nature of glutamatergic dysfunction in schizophrenia is yet to be 
determined, however, since postmortem findings are difficult to interpret and are 
extremely diverse. Decreased glutamatergic synaptic activity has been suggested by 
reports of increased glutamate uptake and kainate receptor binding in the prefrontal 
cortex of patients with schizophrenia (Deakin et al., 1989); whereas, kainate receptor 
binding has been reported to be decreased in the putamen, hippocampus, and 
parahippocampal gyrus (Kerwin et al., 1988). 
In an animal model that explores glutamate excitotoxicity in relation to other 
proposed neuropathological features of schizophrenia, Bardgett and colleagues studied 
the effects of ventricular kainate injection in rats (Csernansky et al., 1996); (Bardgett et 
al., 1995). They observed a dose-dependent loss of neurons that was regionally specific 
for the ventral and dorsal hippocampus, thalamus, and piriform cortex. An increase in 
dopamine receptor binding was also noted in the nucleus accumbens, which probably 
represented a neurochemical response to denervation of limbic control afferents after 
their destruction; and behavioral hyperactivity. Thus, by creating a diffusely excitotoxic 
state, the investigators were able to induce specific limbic system neuropathology and 
neurochemical alterations similar to those seen in human postmortem studies. 
 
3.  Epilepsy 
Involvement of excitatory amino acids in epilepsy is well documented. A large 
number of animal models of epilepsy have indicated a causal role for the glutamate 
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receptor family. An increased sensitivity to the action of glutamate at NMDA receptors is 
seen in hippocampal slices from kindled rats and in cortical slices from, or adjacent to, 
cortical foci in human epilepsy (Hwa and Avoli, 1991).  This leads to an enhanced entry 
of Ca2+ into neurons during synaptic activity that can be detected with ion-specific 
microelectrodes (Pumain et al., 1987).  Excessive stimulation of glutamatergic pathways 
or pharmacological manipulation resulting in glutamate receptor activation can 
precipitate seizures. Evidence from human tissue supports the role of amino acids in 
epilepsy. 
Epilepsy is one of the most common neurological disorders affecting mankind. It 
is a syndrome of unpredictable spontaneous recurrence of seizures, first described in 
Hippocrates’s “On the Sacred Disease” over 2500 years ago. Its prevalence ranges from 
1.5 to 19.5 per 1000, depending on the geographical area and the ethnic group (Hauser et 
al., 1998). Compared with marked improvements in diagnostic and treatment modalities, 
however, the understanding of the basic pathophysiological mechanisms of epilepsy 
remains rather elusive. 
The term “epileptic brain damage” has traditionally been used to refer to the 
selective pattern of damage found in patients with chronic epilepsy. More recently, it is 
also used to refer to the similar pattern of damage described in animals or humans after 
prolonged seizures.  Since Bouchet and Cazauvieilh first noted that one or both Ammon’s 
horns in the brains of some epileptic patients were small and “hard,” the association of 
epilepsy with selective neuronal death and structural changes in the hippocampus has 
been recognized by many neuropathologists. 
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Glutamate has absolutely been implicated in epileptic seizures. Microinjection of 
glutamate into neurons produces spontaneous depolarizations around one second apart, 
and this firing pattern is similar to what is known as paroxysmal depolarizing shift in 
epileptic attacks. It has been suggested that a drop in resting membrane potential at 
seizure foci could cause spontaneous opening of voltage-operated calcium channels 
(VOCCs), leading to glutamate release and further depolarization. It is likely that both 
apoptosis and necrosis may occur in the same neuronal population in association with the 
epileptic damage. The mode of neuronal death may be determined by the severity of the 
insult, different environmental factors (growth factors, synaptic connections) and the 
susceptibility of each neuron, involving glutamate receptor subtypes/subunits, threshold 
of activation, and calcium-buffering capacity (Bonfoco et al., 1995). 
 Excessive electrical discharges induce massive release of excitatory 
neurotransmitters that activate receptors, open ionic channels, and presumably induce an 
excessive increase in intracellular calcium. Excitotoxicity appears to mediate neuronal 
death induced by epileptic seizures for three reasons. 
First, the pattern of selective damage has a close relationship with the network 
across which seizure activity is propagated; for example, limbic seizures produce damage 
in a  wide variety of nuclei involved in limbic seizure activity (Collins and Olney, 1982). 
Second, the cytopathological changes occurring in vulnerable hippocampal or cortical 
neurons are quite similar to the changes induced by glutamate, kainate, or other 
excitotoxic agents. Third, NMDA antagonists can protect against the acute neuronal 
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damage induced by epileptic seizures in various animal models (Fariello and Garant, 
1992). 
Thus, it appears that selective neuronal death likely plays an important role in this 
process in humans. Further insight into the mechanisms involved may provide a window 
of opportunity for the prevention of epilepsy. 
 
4. Trauma 
 
A number of major acute CNS injury syndromes, as indicated, including those 
associated with stroke (Rothman and Olney, 1986); (Faden et al., 1982a); (Ikonomidou et 
al., 1996), trauma (McDonald et al., 2000), hypoglycemia, and status epilepticus are 
believed to be triggered by excess activation of glutamate receptors by endogenous 
excitotoxins; primarily glutamate, but probably also aspartate, and possibly certain sulfur-
containing amino acids. Excessive release and/or impaired uptake of endogenous 
excitotoxins occur in each of these conditions, leading to extracellular accumulation of 
excitotoxins at EAA receptors, and subsequent acute degeneration of neurons by the 
described excitotoxic mechanism (Rothman and Olney, 1986); (Faden et al., 1982a). 
In head trauma, increased intracranial pressure is a major source of morbidity and 
mortality. An excitotoxic mechanism may play a major role in raising the intracranial 
pressure. An excessive stimulation of EAA receptors causes the hyperstimulated neurons 
and the surrounding astroglia to accumulate intracellular fluid, transferring a large 
volume of fluid from the vascular to the intracellular compartment. Depending on the 
severity of the trauma, hundreds of thousands or millions of CNS cells will participate in 
this pathological process (Olney et al., 1986a); (Faden et al., 2005); (Faden, 1993). 
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5. Stroke and Other Disorders 
Excitotoxicity caused by glutamate toxicity is a major destructive process seen in 
strokes and other forms of brain ischemia, although the relationship is complex. 
Prolonged periods of anoxic insult to neuronal tissue, such as during cardiac arrest or 
thrombotic stroke, often result in ischemic cell damage and neurotoxicity. Oxygen 
depletion precipitates a depletion of energy stores within neuronal and glial cell 
compartments, with a concomitant acidosis and release of free radicals. The depletion of 
energy stores affects cellular metabolism, energy-dependent ion pumps, and the ability of 
cells to maintain resting membrane potential. 
Consequently, depolarization of cells results in action potentials, and the 
subsequent release of glutamate from pre-synaptic terminals. The released glutamate then 
activates postsynaptic AMPA and NMDA receptors. The entry of Ca2+ through the 
NMDA receptor complex and voltage-sensitive Ca2+ channels increases the intracellular 
concentration of Ca2+. This elevation of intracellular Ca2+ will trigger a cascade of 
second-messenger systems, many of which remain activated long after the initial stimulus 
is removed (Obrenovitch, 1999); (Obrenovitch et al., 2000); (Obrenovitch and Richards, 
1995); (Obrenovitch and Urenjak, 1998). 
This inability of the neurons to maintain a resting potential precipitates a positive 
feedback loop that leads to neuronal cell injury or death. The two regions most heavily 
damaged by interruption in blood supply are the hippocampus and striatum. 
The demonstration that neuronal injury could be reduced by antagonists of 
excitatory neurotransmission during recovery from global ischemia has been a major 
factor driving neuroprotection research. These studies provided convincing evidence that 
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ischemic neuronal injury was reversible well after reperfusion, allowing for a 
“therapeutic window.” Global ischemia represents only one type of clinical ischemia, 
affecting a region of the brain, which, while critical, represents a small portion of the 
human brain. Early studies concluded that ischemic injury occurs when energy failure 
results in a massive release of glutamate into the extracellular space. 
Several subsequent studies have shown that the protective effects of glutamate 
receptor antagonists can be observed long after the acute ischemic glutamate release has 
ended, and the classic signs of glutamate toxicity are not observed early in ischemia 
(Obrenovitch et al., 2000); (Obrenovitch, 1999); (Obrenovitch and Richards, 1995); 
(Obrenovitch and Urenjak, 1998). Some researchers suggest that the protective effects of 
glutamate antagonists may be due to hypothermia rather than receptor blockade under 
certain conditions (Vornov et al., 1998); (Vornov and Coyle, 1991). 
As an aside, neurolathyrism is a crippling motor neuron disorder caused by 
chronic ingestion of a legume which contains beta-N-oxalylamino-L-alanine (BOAA or 
ODAP), an acidic amino acid with powerful excitotoxic properties mediated through non-
NMDA glutamate receptors (Olney et al., 1986b). This spastic disorder occurs in East 
Africa and India. The action of BOAA, identified as the toxin in this chickpea, acts at 
AMPA receptors in the spinal cord, resulting in observed degeneration of lower and 
upper motor neurons. 
If chronic exposure to BOAA, an exogenous excitotoxin, acts selectively at non-
NMDA glutamate receptors and can cause motor neurons to degenerate slowly over 
months or years, it may be possible for endogenous glutamate acting at the same 
 
 
31 
receptors to cause chronic degeneration of motor neurons in idiopathic motor neuron 
disorders such as amyotrophic lateral sclerosis (Olney, 1990a); (Olney, 1990b). 
Interestingly, one alternative hypothesis for the pathogenesis of Parkinson’s 
Disease, in which nigro-striatal dopaminergic neurons are lost, is that excitotoxic 
mechanisms, possibly acting in concert with oxidative stress (Coyle et al., 1981) or 
impaired energy metabolism (Albin and Greenamyre, 1992) may play a role. These 
factors have been postulated to underlie a number of chronic, neuron phenotype-specific 
neurodegenerative disorders. 
The evidence, however, is minimal, although the study by Turski is often quoted, 
whereby NMDA antagonists protected the substantia nigra from direct injection of DA-
specific neuronal toxins (Turski et al., 1987). The finding could not be replicated, 
however, and the number of NMDA receptor binding sites in the substantia nigra is low 
(Sonsalla et al., 1998). Other work is continuing in this field, involving spontaneous 
degeneration of the substantia nigra neurons in a mutant Weaver mouse, which may 
involve excitotoxic mechanisms (Slesinger et al., 1996). 
Both exogenous and endogenous excitotoxins are implicated in acute CNS injury 
syndromes. Domoate encephalopathy is an excellent example of an acute CNS injury 
syndrome caused by human exposure to an exogenous excitotoxin. In 1987, an outbreak 
of food poisoning in Canada affected 145 people, some of whom did not survive (Olney 
et al., 1990). Some survivors sustained permanent brain damage and continued to show 
signs of cognitive deficits, especially impairment of memory, many months after the 
initial incident. All of the afflicted individuals had eaten mussels which had high 
concentrations of domoate, an excitotoxic analog of glutamate similar to kainate, which 
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produces persistent seizures (status epilepticus) in adult rats (Stewart et al., 1990). Status 
epilepticus was a prominent feature in the symptomatology displayed by the poisoned 
individuals who ate the mussels. Primarily aged adults displayed the seizure activity after 
the domoate poisoning, leading to the conclusion that the aged brain may actually display 
a kainate receptor, which is a potentially sensitive mediator of excitotoxicity. 
Notably, the brain damage induced by kainate in rats can be prevented by 
pretreatment with an NMDA antagonist (Clifford et al., 1990). Thus, it has been 
postulated that although the persistent seizure activity induced by either domoate or 
kainate is triggered by activation of kainate receptors, it is the excessive seizure-mediated 
release of an excitotoxic transmitter, presumably glutamate, at NMDA receptors that is 
apparently responsible for most of the brain damage that ensues (Olney, 2002); (Olney 
and Farber, 1995). 
Additionally, disorders of excitatory amino acid transmission have been 
implicated in amyotrophic lateral sclerosis (ALS) and in the chronic neurodegenerative 
diseases olivopontocerebellar atrophy and Huntington’s chorea. 
 
C. Thyrotropin-Releasing Hormone (TRH) Protirelin 
 
1.   Biosynthesis of TRH 
 
Protirelin (TRH) (Figure 1) is a 3-amino-acid neuropeptide with the highest 
density of its receptors (TRH R-1 and TRH R-2) throughout the CNS, highly expressed 
in pituitary, hippocampal dentate gyrus, and amygdalae (Heuer et al., 2000); (Kubek et 
al., 1977); (Nillni and Sevarino, 1999); (Sharif, 1989). TRH and its analogues have been 
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shown to act as modulators in many classical neurotransmitter systems, including 
norepinephrine (Keller et al., 1974); (Rastogi et al., 1981), acetylcholine (Narumi et al., 
1983); (Toide et al., 1993), GABA (Mouginot et al., 1991), serotonin (Rastogi et al., 
1981); (Sattin et al., 1992), dopamine (Bennett et al., 1989); (Marsden et al., 1989), and 
glutamate (Renaud and Martin, 1975). 
 
 
Figure 1. (Courtesy of Prof. M. Kubek) 
 
It was discovered in the 1970s that TRH is produced in the paraventricular 
nucleus of the hypothalamus (PVN), and stimulates the biosynthesis and secretion of 
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thyroid-stimulating hormone (TSH) from the anterior pituitary (Harris et al., 1978);  (Hall 
et al., 1970). TSH then stimulates thyroid hormone biosynthesis and release (Morley, 
1981). TRH is central in regulating the hypothalamic-pituitary-thyroid (HPT) axis. It 
influences the release of other hormones, including PRL, GH, vasopressin, and insulin 
(Bowers and Schally, 1970); (Bowers et al., 1971); (Wilber and Utiger, 1968); (Takahara 
et al., 1974), and the classic neurotransmitters noradrenaline and adrenaline (Griffiths, 
1985). 
Notably, TRH is present in many brain loci outside of the hypothalamus, 
supporting a potential role as a neuromodulator or neurotransmitter outside of traditional 
HPT axis function (Metcalf, 1974); (Hedner et al., 1981). For example, TRH is 
implicated as a modulator of seizure activity (Kubek et al., 1989) as well as 
gastrointestinal function (Tache et al., 1989). 
TRH has been found outside the central nervous system (CNS) in the 
gastrointestinal tract, pancreas, reproductive tissues (placenta, ovary, testis, seminal 
vesicles, and prostate) as well as in retina, and blood elements (Lechan, 1987). Nillni 
states in his 1999 review that the widespread distribution of TRH within and outside the 
CNS supports a diverse range of roles for this molecule, roles likely to involve many 
functions outside of the traditional HPT axis (Nillni and Sevarino, 1999). 
TRH is thus not only associated with regulation of the HPT (hypothalamic-
pituitary-thyroid) axis, but has also been found to function as a neuropeptide in specific 
areas of the brain and other tissues (Gary et al., 2003); (Nillni and Sevarino, 1999). TRH 
is synthesized in neurons, and then packaged into and stored in vesicles, along with the 
catecholamine and other classical neurotransmitters. TRH is then released at synaptic 
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terminals and binds with high affinity to specific neuronal receptors (Nillni and Sevarino, 
1999). 
In summary, the fact that TRH and its receptors have been found in certain 
regions of the CNS, including a high density of both in the hippocampus, and have been 
hypothesized to function in neuromodulation (Gary et al, 2003); (Kubek, et al., 1977); 
(Nillni and Sevarino, 1999) was critical to the design of this study. 
Nillni discusses the biosynthesis of TRH in his 1999 review. He begins with the 
processing of pro-TRH. The discovery of the rat prepro-TRH sequence in 1986 was 
critical for understanding the processing of pro-TRH to TRH and non-TRH peptides. Rat 
prepro-TRH is a 29-kDa polypeptide composed of 255 amino acids. The rat precursor 
contains an N-terminal 25-amino acid leader sequence, 5 copies of the TRH progenitor 
sequence Gln-His-Pro-Gly flanked by paired basic amino acids (Lys-Arg or Arg-Arg), 4 
non-TRH peptides lying between the TRH progenitors, an N-terminal flanking peptide, 
and a C-terminal flanking peptide (Lechan et al., 1986b); (Lechan et al., 1986a). 
 The N-terminal flanking peptide (prepro-TRH25–50-R-R-prepro-TRH53–74) is 
further cleaved at the C-terminal side of the arginine pair site to render prepro-TRH25–50 
and prepro-TRH53–74, thus yielding a total of 7 pro-TRH-derived peptides (Nillni and 
Sevarino, 1999). 
The biosynthesis of TRH and other pro-TRH-derived peptides follows the same 
prohormone-processing mechanisms, starting with mRNA-directed ribosomal translation, 
followed by posttranslational-limited proteolysis of the larger precursor, proTRH. This 
process occurs while pro-TRH is transported from the trans-Golgi network (TGN) to 
newly-formed immature secretory granules (ISGs) (Cruz and Nillni, 1996). These 
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granules then mature and are targeted to sites of secretion at the plasma membrane of the 
cell. Rat, mouse, and human pro-TRH, similar to other peptide hormone precursors such 
as pro-enkephalin, contain multiple copies of one of its peptide products, in this case, the 
progenitor for TRH, Gln-His-Pro-Gly (Nillni et al., 1993). 
Most of the products derived from pro-TRH are targeted into the regulatory 
secretory pathway (RSP). Cleavage of the precursor to generate biologically active TRH 
occurs at paired basic residues by the action of two serine proteases, which are members 
of the family of prohormone convertases, PC1 and PC2 (Nillni et al., 1995); (Friedman et 
al., 1995); (Schaner et al., 1997), followed by the action of carboxypeptidase-e (CPE) to 
remove the basic residue(s). Gln-His-Pro-Gly is then amidated by the action of glycine α-
amidating monooxygenase (PAM), which uses the C-terminal Gly as the amide donor, 
and the Gln residue undergoes cyclization to a pGlu residue to yield TRH (Nillni and 
Sevarino, 1999). 
 
2.  Inactivation of TRH 
TRH is degraded by separate enzymes, which are cytosolic and membrane bound, 
resulting in several physiologically active metabolites (O'Cuinn et al., 1990). In the 
cytosol, TRH degradation occurs via cleavage by pyroglutamate aminopeptidase, 
generating pyroglutamic acid and His-ProNH2 (Browne and O'Cuinn, 1983); (Bauer and 
Kleinkauf, 1980). Occasionally, this His-ProNH2 metabolizes/cyclizes to cyclo(his-pro), 
which does not degrade any further (Peterkofsky et al., 1982); (Prasad et al., 1982). 
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Additionally, deamidation may be catalyzed by another enzyme, a post-proline-
cleaving endopeptidase. In this instance, cleavage forms free-acid TRH, which was used 
in this study since it is an inactive metabolite of TRH (Emerson et al., 1980). 
Nillini stated in his 1999 review that the rapid degradation of TRH after release 
from cells represents a significant drawback in its potential use as a therapeutic agent. To 
overcome these difficulties, various analogs have been synthesized and evaluated by 
many groups of investigators, including O’Leary and colleagues in 1995. Specific 
enzymes that act on TRH are found in many tissues including the brain, spinal cord, 
pituitary, liver, kidney, pancreas, adrenal glands, and blood. These enzymes not only 
inactivate TRH, but act in concert with biosynthetic processes to determine the steady 
state levels of TRH, and its metabolites. 
The four key enzymes mentioned above which breakdown TRH: PAP I, PAP II, 
and thyroliberinase, give rise to the stable cyclized metabolite CHP (also known as 
histidyl-proline-diketopiperazine or His-Pro-DKP), and prolyl endopeptidase gives rise to 
the deamidated free acid, TRH-OH (Yanagisawa et al., 1980). In the CNS, the soluble 
PAP I and prolyl endopeptidase, and the membrane-bound PAP II, are the principal 
enzymes acting to metabolize TRH (Kelly, 1995).  
TRH degradation in serum and many peripheral tissues is through the serum 
enzyme thyroliberinase (Nillni and Sevarino, 1999). As will be discussed, we used the 
stable analogue of TRH, 3Me-H-TRH (pGlu-3-His-Pro-NH2), since it is much more 
biologically active than TRH due to its binding affinity to the TRH receptor (Rivier et al., 
1972); (Sharif et al., 1990). The 3Me addition also makes the analog more resistant to 
enzymatic degradation (Griffiths et al., 1989). 
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Nillni states that the physiological significance of the soluble enzymes PAP I and 
prolyl endopeptidase within the brain and spinal cord are unclear, since in the case of 
neurotransmitter inactivation, TRH is probably degraded outside the neuron by 
ectoenzymes located on the cell surface, or within lysosomes after endocytosis. 
Membrane-bound ectoenzymes that are specific for TRH, such as PAP II, are better 
located for hydrolysis of synaptically released peptides. Soluble enzymes are better 
situated to control degradation of TRH during its transport in the hypophyseal portal 
vessels and systemic TRH. The exact mechanisms that control the amount of TRH that 
ultimately reaches the pituitary remain to be elucidated (Nillni and Sevarino, 1999). 
 
 3. Receptor Distribution in the Hippocampus 
 
TRH receptor type 1 (TRH-R1) was cloned originally from mouse pituitary cells 
(Straub et al., 1990) and then from rat (Zhao et al., 1993); (de la Pena et al., 1992); (Sellar 
et al., 1993), human (Matre et al., 1993); (Yamada et al., 1993); (Duthie et al., 1993), 
chicken (Sun et al., 1998), and bovine (Takata et al., 1998) tissues. TRH receptor type 2 
(TRH-R2) was cloned from rat central nervous system (Itadani et al., 1998); (Cao et al., 
1998); (O'Dowd et al., 2000). 
Both receptor subtypes exhibit similar binding affinities for many TRH analogs, 
as well as similar activation of phosphoinositide-calcium signal transduction pathway by 
TRH (Wang and Gershengorn, 1999). Homogenate analysis and autoradiographical 
techniques have been used to measure the distribution of TRH receptors in the brain 
(Pilotte et al., 1984); (Sharif and Burt, 1985); (Manaker et al., 1985); (Mantyh and Hunt, 
1985); (Pazos et al., 1985); (Burt and Snyder, 1975); (Manaker et al., 1986). 
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Furthermore, TRH receptor density has been studied in anterior pituitary cells and 
in transfected oocytes from frogs, in which case the downregulation involved changes in 
degradation or synthesis of the receptors (Hinkle and Tashjian, Jr., 1975); (Halpern and 
Hinkle, 1981); (Oron et al., 1987). Heuer and colleagues showed that TRH receptor 
mRNA is localized mainly in the granule cells of the ventral hippocampus, as well as in 
pyramidal and subicular neurons (Heuer et al., 2000). 
Anatomically, a high density of TRH receptors is distributed in the anterior 
pituitary, spinal cord and limbic system, especially the hippocampal dentate gyrus. Thus, 
the simplest explanation for TRH inhibition is through stimulation of inhibitory cells such 
as GABA neurons in the dentate gyrus (Manaker et al., 1985); (Sharif, 1989); (Sharif et 
al., 1990). TRH-containing neurons have been located in the granule cell layer of the 
hippocampal dentate gyrus, pyramidal cells of the cornu ammonis (CA), the amygdala, 
and the piriform and entorhinal cortices (Hokfelt et al., 1975); (Merchenthaler et al., 
1989); (Kubek et al., 1993); (Low et al., 1989a). 
It has been shown that TRH mRNA and TRH receptor mRNA exist in granule 
cells of the dentate gyrus, which are excitatory and contain both ionotropic and mGluR 
subclasses (Heuer et al., 1998); (Blumcke et al., 1996); (Calza et al., 1992). 
Regional differences for TRH receptors have been observed. Specifically, TRH-
R2 was highly abundant in the precommisural hippocampus, but no specific TRH-R2 
signal was detected in the granular or pyramidal cell layers. Heuer reported that a strong 
TRH-R1 expression was noted in the ventral dentate gyrus, and a subpopulation of 
neurons containing TRH-R1 was found scattered within the granular layer of the dentate 
gyrus and the stratum radiatum (Heuer et al., 2000). 
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Heuer also noted that Ammon’s horn was devoid of TRH mRNA signals, but both 
receptor isoforms were found in the subiculum. Additionally, he found a robust and 
specific labeling for TRH mRNA in a distinct subpopulation of dentate gyrus granular 
cells, which had not been previously reported (Segerson et al., 1987); (Heuer et al., 
2000). 
Thus, TRH-R1 and TRH-R2 receptors and group I metabotropic glutamate 
receptors mGluR1,5 are co-localized in the granule cells of the hippocampal dentate gyrus, 
and are the only receptor subclass to share the same signaling cascade (Gαq/11) in these 
neurons. 
 
4. Receptor Physiology 
TRH functions through a seven transmembrane (metabotropic) G-protein coupled 
receptor as its second messenger system (Yu and Hinkle, 1998). Notably, both TRH and 
metabotropic group I (mGluR1,5) receptors are expressed in the dentate granule cells of 
the hippocampal dentate gyrus. The TRH receptor is similar to the G-protein coupled 
family of receptors, in that there is are seven transmembrane-spanning domains and two 
glycosylation sites in the N-terminus. The third intracellular loop is an amphipathic helix, 
which binds a G-protein. Cysteine residues, which may form a disulfide bond, are present 
in extracellular loops 1 and 2; and 15 of the last 52 amino acids are serine or threonine 
residues. The most likely candidates for protein kinase C phosphorylation are 3 residues 
in loops 3 and 4 residues in the C-terminus. The mouse and rat pituitary receptors have 
been cloned and sequenced (Straub et al., 1990); (Zhao et al., 1993). 
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The Gαq/11 subunit, which is shared by both TRH and group I mGluRs, is critical 
when one considers the proposed mechanism of heterologous receptor downregulation as 
one mechanism whereby TRH exerts its neuroprotective effect on cells, slices, and 
neuronal cultures. 
The binding of TRH to its receptor activates phospholipase C by coupling through 
a GTP-dependent protein, as shown by pituitary cell studies (Martin et al., 1986).  
Mechanistically, phospholipase C (PLC) catalyzes the hydrolysis of phosphatidylinositol 
4,5 bisphosphate (PIP2) to the second messengers myoinositol 1,4,5-trisphosphate (IP3) 
and 1,2-diacylglycerol (DAG) (Gershengorn, 1989). IP3 mobilizes intracellular calcium; 
whereas, DAG activates protein kinase C (PKC), which is a phosphorylating enzyme 
(Berridge and Irvine, 1984). Additionally, TRH may also stimulate the production of 
cyclic AMP, which may be a consequence of calcium/calmodulin or PKC-mediated 
adenylate cyclase regulation (Martin, 1989); (Mori et al., 1991); (Iriuchijima and Mori, 
1989). 
 
D. The Hippocampus 
 
1. Anatomic Description 
The hippocampal formation is identified on the medial surface of the temporal 
lobes and extends along the floor of the temporal horn of the lateral ventricle. Three 
major subdivisions are described as the dentate gyrus, the hippocampus proper, and the 
subicular complex, which is part of the parahippocampal gyrus that is contiguous with the 
hippocampal fields. Ammon’s horn, or cornu ammonis (thus CA), is a classic anatomic 
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term describing the hippocampus proper. CA is the term most widely used to describe the 
subfields of the hippocampus: CA1, CA2, CA3, and CA4 (dentate hilus) (Figure 2.) 
 
Figure 2. (Courtesy of Prof. M. Kubek) 
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The trisynaptic pathway is an internal circuit mechanism unique to the 
hippocampus. Viewed in coronal section, the granule cell layer of the dentate gyrus is 
considered to be the first stage of the trisynaptic pathway, and is the target for most of the 
entorhinal afferents. These afferents reach the granule cells via the perforant pathway, 
whose axons perforate the hippocampal fissure. 
The second stage of the trisynaptic pathway is the CA3 subfield. Pyramidal cells 
of this region are the principal targets of granule cell axons. CA3 pyramidal cell axons  
give rise to extensive axonal projections, which extend to the CA1 subfield, as originally 
described by Schaffer in the nineteenth century. The CA1 subfield represents the third 
and last stage of the intrahippocampal trisynaptic loop, and serves as the target for CA3 
pyramidal cell axons (Schaffer collaterals); (Benes and Berretta, 2000). 
The intrahippocampal pathways and neuroanatomy of the hippocampus are thus 
well described, and contain almost all of the major peptide and neurotransmitter systems. 
The hippocampus is used as a model system for mechanisms of synaptic excitation and 
inhibition since it has three major excitatory pathways running from the subiculum to the 
CA1 region. The perforant pathway runs from the subiculum to the granule cells in the 
dentate gyrus hilus. The granule cell axons form the mossy fiber pathway that runs to the 
pyramidal cells the CA3. Finally, the pyramidal cells in the CA3 region send excitatory 
collaterals, Schaffer collaterals, to the pyramidal cells in CA1 (Storm-Mathisen, 1977). 
High affinity uptake of glutamate and aspartate is localized in the terminals of the 
perforant pathway, mossy fibers and pyramidal cell axons. Hippocampal efferents also 
take up aspartate and glutamate. Peak concentrations of gamma-aminobutyrate (GABA) 
occur near the pyramidal and granular cell bodies, corresponding to the site of the 
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inhibitory basket cell terminals, and in the outer parts of the molecular layers. A further 
description of the distribution of glutamate receptors in the hippocampus is in a 
subsequent section (Storm-Mathisen, 1977). 
Cholinergic septo-hippocampal afferents are also present. Serotonin, 
noradrenaline, dopamine and histamine are located/synthesized in afferent fiber systems. 
The hippocampal formation also contains nerve elements reacting with antibodies against 
neuroactive peptides, such as enkephalin, substance P, somatostatin and 
gastrin/cholecystokinin (Storm-Mathisen, 1977). 
On transverse section, the hippocampus is divided into four subfields: CA1, CA2, 
CA3, and dentate hilus. CA2 is between CA1 and CA3 but is not well demarcated. The 
areas of CA3 adjacent to the CA2 region are termed CA3a. The CA3b region is 
approximately the middle third and CA3c is the terminal portion between the superior 
and inferior blades of the dentate gyrus. 
The main cells of the hippocampus are the pyramidal cells, with both their basal 
and apical dendrites. The axons of the pyramidal cells branch into collaterals that project 
within and outside the hippocampus. The collateral axons of the CA3 pyramidal cells that 
synapse on the apical dendrites of the CA1 pyramidal cells are called Schaffer collaterals. 
The second major cell type are basket cells which contain GAD (glutamic acid 
decarboxylase), the gamma-aminobutyric acid (GABA) synthesizing enzyme, and exert 
an inhibitory action on the pyramidal cells. 
The dentate gyrus is a three-layered structure consisting of the molecular layer 
(stratum moleculare), granular layer (stratum granulosum), and the polymorphic layer, 
from superficial to deep. The dentate granule cells are the main cell type of the dentate 
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gyrus. Mossy cells and other interneurons are found in the polymorphic layer in the 
dentate hilus (CA4). 
The axons of granule cells, known as mossy fibers, contain zinc, and make 
excitatory synaptic contacts with the proximal portions of the apical dendrites of the CA3 
pyramidal cells in the stratum lucidum. Mossy fibers also innervate the soma and 
dendrites of polymorphic interneurons (basket cells and mossy cells) in the dentate hilus 
(Teyler and DiScenna, 1984). 
The dendrites of granule cells branch into the molecular layer where the perforant 
pathway (the main hippocampal afferent system originating from the entorhinal cortex) 
makes synaptic contacts. The granule cells then project via mossy fibers to the CA3 
pyramidal cells, which then send Schaffer collaterals to CA1 pyramidal cells. These CA1 
pyramidal cells then project to the subicular complex, which will then project to the 
entorhinal cortex (Teyler and DiScenna, 1984). 
The dentate granule cells are glutamatergic excitatory neurons, which contain 
dynorphin and cholecystokinin (CCK) in the terminal boutons of their axons (mossy 
fibers). Inhibitory interneurons containing GAD exist throughout the hippocampus. 
Basket cells are GABAergic inhibitory interneurons, which are also immunoreactive for 
CCK. Somatostatin (SS) and neuropeptide-Y (NPY) immunoreactive interneurons are 
found in the hilar region and the stratum oriens of the CA1 subfields. The mossy cells are 
found in the dentate hilar region, and have excitatory synapses onto the GABA 
interneurons (basket cells). This provides tonic baseline inhibition and mediates phasic 
feedback inhibition to the granule cells (Teyler and DiScenna, 1984). 
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2. Receptor Distribution 
  
Although glutamate receptors are ubiquitously found in the cortex, there are some 
notable differences in the distribution of receptor subtypes (Choi, 2003); (Cotman and 
Monaghan, 1988). In the neocortex, NMDA receptors are particularly dense within the 
outer two layers; whereas, high-affinity kainate receptors predominate in layers 5 and 6. 
In the hippocampus, which was the focus of these experiments, the trisynaptic 
loop contains glutamate and aspartate excitatory amino acid neurotransmitters; although 
different EAA receptors are found along the loop (Storm-Matheson, 1981); (White et al., 
1977). High densities of NMDA and kainate (KA) receptors are found in the dentate 
gyral molecular layer. In contrast, NMDA receptors are absent in the CA3 stratum 
lucidum, which is the mossy fiber termination zone. The stratum oriens and radiatum of 
subfield CA1, which receive the Schaffer collaterals, contain high densities of both 
AMPA and NMDA receptors (Monaghan et al., 1983); (Monaghan and Cotman, 1985); 
(Unnerstall and Wamsley, 1983). 
Regarding group II mGluR distribution in the hippocampus, it has been shown in 
general that mGluR2 receptors are localized on preterminal axons of glutamate neurons, 
and serve as pre-synaptic modulatory receptors in the hippocampus, where they function 
via a negative feedback mechanism to suppress further release of glutamate. Conversely, 
mGluR3 receptors are found most often post-synaptically on neurons and expressed in 
glia, where their functional role is less clear (Shigemoto et al., 1997). 
Notably, the pre-synaptic localization of the mGluR2 to glutamate preterminal 
axons has been most clearly defined within the hippocampal formation, where mGluR2 
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immunoreactivity illustrates a primary localization to subfields corresponding to the 
medial perforant and mossy fiber pathways (Shigemoto et al., 1997). Unilateral lesions of 
the entorhinal cortex, which contains cell bodies of the perforant path neurons, lead to 
ipsilateral loss of mGluR2/3 immunoreactivity (Shigemoto et al., 1997). 
 Unlike wild-type animals, knockout mice deficient in mGluR2 receptors showed 
no immunostaining of mGluR2 within the stratum lucidum of CA3 (mossy fiber terminal 
field) or the stratum lacunosum moleculare of CA1 (medial perforant path terminal field) 
of hippocampus (Yokoi et al., 1996). In addition, in mGluR2-deficient mice, long-term 
depression induced by low-frequency stimulation of the mossy fiber CA3 synapses was 
abolished, indicating that pre-synaptic mGluR2 receptors are essential for inducing long-
term depression at this synapse, illustrating an important role in the modulation of 
neuronal excitability. However, Schoepp states that mGluR2 knockout animals appear to 
be functionally normal, with no alteration in basal synaptic transmission. Thus, mGluR2 
receptors are not believed to play a prominent role in the acute regulation of excitatory 
synaptic transmission (Schoepp, 2001). 
Regarding the distribution of group III mGluR subtypes (mGluR1,5) within the 
hippocampus, it was reported in 1981 by Koerner and colleagues that the L-2-amino-4-
phosphonobutyric acid (L-AP4), an acidic amino acid analog, selectively suppressed 
glutamate excitations pre-synaptically in the hippocampal lateral perforant pathway. This 
inhibitory activity of L-AP4 on glutamate excitations was also observed in other 
preparations, including the mossy fiber synapse, lateral olfactory tract, and spinal cord 
(Koerner and Cotman, 1981); (Schoepp, 2001); (Thomsen et al., 1992); (Thomsen, 1997). 
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Until the 1990s, pre-synaptic inhibition induced by L-AP4 was ascribed to what 
was labeled the L-AP4 receptor. After the cloning of the group III mGluRs, which 
Nakanishi defined by their sensitivity to L-AP4, it was recognized that certain group III 
mGluR subtypes might be responsible for L-AP4-induced suppression of glutamate 
release (Nakanishi, 1992). The mGluR7, mGluR8, and possibly mGluR4 receptors have 
been suggested as candidates for the pre-synaptic effects of L-AP4 in the brain (Thomsen, 
1997); (Schoepp, 2001). 
In certain subfields of the hippocampus, both mGluR4 and mGluR8 receptors have 
been shown to be expressed to a certain extent, and their possible role in synaptic 
transmission at hippocampal pathways has been reported (Bradley et al., 1998); (Bradley 
et al., 1996); (Shigemoto et al., 1997); (Schoepp, 2001). Studies have shown selective 
labeling of mGluR8 receptors to the terminal fields of the lateral perforant pathway (CA3 
stratum lacunosum moleculare), and loss of this labeling following perforant path lesions 
(Shigemoto et al., 1997). While mGluR8 receptors are relatively restricted to the terminal 
subfields of the dentate gyrus, the initial work of Bradley and colleagues demonstrated 
that mGluR4a staining was in cell bodies and dendrites of pyramidal neurons, granule 
cells, and scattered interneurons throughout the hippocampus (Bradley et al., 1996). 
Three years later, however, this same group, using a more specific antibody, 
suggested a more limited hippocampal distribution of mGluR4a.  High expression was 
noted in the molecular layer of the dentate gyrus, as well as in the stratum moleculare of 
CA1 and the stratum oriens of the CA3 area, which was not present in the mGluR4a 
knockout mouse (Bradley et al., 1998); (Bradley et al., 1999). Via electron microscopy, 
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mGluR4 receptors are found post-synaptically at asymmetrical (presumably 
glutamatergic) synapses, and pre-synaptically at both asymmetrical and symmetrical 
(presumably GABAergic) synapses (Bradley et al., 1999); (Schoepp, 2001). 
Thus, mGluR4 receptors may have pre- and postsynaptic functions, and they may 
be involved in both homo- and heterosynaptic modulation in these brain regions. Gerlai 
and colleagues have reported a possible role for mGluR4 receptors in hippocampal 
processing of spatial information (Gerlai et al., 1998); (Schoepp, 2001). 
Bradley reported that mGluR7 receptors are highly expressed throughout the 
forebrain, brainstem, and spinal cord regions of the CNS (Bradley et al., 1998). In 
particular, mGluR7 receptors may represent an autoreceptor in certain synapses that 
provide negative feedback to limit further release of glutamate under normal 
physiological conditions of excitatory synaptic transmission (Schoepp, 2001). Shigemoto 
and colleagues showed that mGluR7a receptor immunoreactivity in the rat hippocampus 
was restricted to the pre-synaptic grid, or the site of vesicle fusion. The lower affinity of 
glutamate for mGluR7 receptors was consistent with its localization in the synaptic cleft 
and function as an autoreceptor (Shigemoto et al., 1997); (Schoepp, 2001). 
In general, mGluR7 receptor protein and mRNA are relatively more widespread in 
distribution throughout the neuro-axis when compared with other pre-synaptic mGluRs 
(e.g., mGluR2, mGluR4, and mGluR8), possibly indicating a more prominent role in 
normal regulation of synaptic glutamate release. Nevertheless, like other mGluRs, 
mGluR7 expression is more concentrated in certain areas and appears to be specifically 
targeted to certain synapses. Thus, not all glutamatergic neurons appear to express (or 
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need) an mGluR7 autoreceptor regulatory mechanism to maintain normal excitatory 
functions (Schoepp, 2001). 
The expression of mGluR7 receptors in glutamatergic nerve terminals of the 
perforant path is supported by loss of mGluR7a immunoreactivity following lesions of 
entorhinal cortex (Shigemoto et al., 1997). Additionally, colchicine lesions of the dentate 
granule cells also produced loss of mGluR7 receptor immunoreactivity in the CA3 of the 
hippocampus, indicating a pre-synaptic role of mGluR7 in the mossy fiber pathway. 
Terminals of pyramidal neurons, which were pre-synaptic to the population of 
interneurons expressing postsynaptic mGluR1 receptors, expressed ~10-fold higher levels 
of mGluR7 receptors when compared with terminals making synaptic contacts with other 
pyramidal neurons or interneurons, suggesting that mGluR7 receptors may regulate 
release of glutamate at certain synapses based on what other receptors are expressed post-
synaptically (Schoepp, 2001). 
Boudin and colleagues suggested that the targeting of the mGluR7a receptor to the 
pre-synaptic membrane is dependent upon binding to PICK1, a PDZ domain-binding 
protein. The PDZ domain-binding site for the mGluR7a receptor is within the extreme 
carboxyl terminus of the receptor, and this sequence appears to confer PICK1 binding and 
receptor targeting, as mGluR2, another pre-synaptic mGlu receptor, did not bind to PICK1 
and an mGluR7a receptor mutant lacking critical amino acids led to lack of pre-synaptic 
receptor clustering in hippocampal neurons (Boudin et al., 2000); (Schoepp, 2001). 
As stated previously, glutamate acts through both fast ionotropic (AMPA, 
NMDA, kainate) and slower G-protein coupled metabotropic receptors (mGluRs). The 
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metabotropic receptors (mGluR1-8) generate changes that are slower as well as longer 
lasting in neuronal heterotrimeric G-protein signaling cascades. The different 
metabotropic glutamate receptors are the foremost receptors, which have been shown to 
mediate extrasynaptic glutamatergic signaling, and are distributed throughout the 
hippocampal subfields (Blumcke et al., 1996); (Vignes et al., 1998); (van Hooft et al., 
2000); (Conn and Niswender, 2006). 
The first physiological evidence for the remote effects of synaptically released 
glutamate in the hippocampus, however, came from examining NMDA receptors, which 
have an affinity for glutamate of the same order of magnitude as the metabotropic ones. 
The NMDA receptors are activated at low micromolar (µM) concentrations, with a KD≈ 
100-fold lower than AMPA receptors (Patneau and Mayer, 1990); (Kullmann et al., 
1999a). 
Glutamate can act at remote receptors in the hippocampus, and thus does not act 
as a point-to-point messenger, exclusively. Kullmann and colleagues noted that it is 
difficult to determine whether the modulatory effects of glutamate are actually confined 
to a small spatial and temporal domain around the synaptic release event, or are instead 
spread diffusely to nearby receptors, or even to neighboring synapses. Glutamate may 
thus function as a diffuse neuromodulator, in addition to its conventional role in fast 
excitatory transmission. Given that glutamate is also an excitotoxin, Kullmann and others 
speculated that the feedback regulation via metabotropic receptors may thus act to protect 
neurons from excessive excitation (Kullmann et al., 1999a); (Kullmann, 1999b). 
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Blumcke and colleagues showed that immunoreactivity for mGluR2/3, members of 
class II mGluRs, was present in all principle neurons in the hippocampal dentate gyrus, as 
well as in the CA4, CA3 and CA2 regions. Pyramidal cells of the CAI region exhibited 
only weak labeling for mGluR2/3 in the study; additionally, glial cells were also 
mGluR2/3-immunoreactive. The reaction obtained with an antiserum directed against 
mGluR4a, a member of class III mGluRs, was confined to the mossy fiber projection field 
in CA3 stratum lucidum (Blumcke et al., 1996). 
The experiments detailed in this thesis investigated the phenomenon of 
heterologous receptor downregulation, involving the second messenger cascade shared by 
both the metabotropic glutamate receptors (specifically mGluR1,5)  as well as the TRH 
receptors localized in the hippocampus. 
 
E. Heterologous Receptor Desensitization 
 
1. Background 
 
Synaptic receptors have two major functions: recognition of specific transmitters 
and activation of effectors. The receptor first recognizes and binds a transmitter in the 
external environment of the cell; then, as a consequence of binding, the receptor alters the 
biochemical state of the cell. 
Milligan described the phenomenon by which cells and tissues develop reduced 
sensitivity over time to the continued presence of a stimulus at constant intensity as 
“desensitization.” In homologous desensitization, treatment with an agonist results in 
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decreased sensitivity to the agonist, but not to other signals that work through distinct 
receptors. Milligan and colleagues proposed receptor-mediated downregulation of the 
shared cellular G-protein subunits as a mechanism for the development of sustained 
heterologous receptor desensitization (Milligan and Green, 1997). This is described as a 
more general type of desensitization, such that reduced sensitivity to several different 
agonists develops. 
TRH administration has been shown to induce the sub-cellular redistribution and 
down-regulation of its intracellular signaling protein, Gαq/11. Svoboda and colleagues 
showed that prolonged exposure to TRH resulted in selective and robust redistribution 
and down-regulation of Gαq/11 when both the TRH receptor, TRH-R1, and Gαq/11 are 
overexpressed in human embryonic kidney 293 (HEK293) cells (Svoboda et al., 1996). 
Furthermore, Kim and colleagues showed that sustained exposure to TRH 
downregulates Gq proteins in HEK293 and GH-3 cells, again, the same heterotrimeric G-
protein used by glutamate in its metabotropic second messenger cascade (Kim et al., 
1994). In these experiments, it should be noted that the TRH receptor R1 as well as Gαq/11 
were overexpressed in the HEK 293 cells. 
This desensitization of G-protein coupled receptors is considered to be a 
mechanism of adaptation to the continuous or repeated presence of stimuli, through 
mechanisms which are complex, and may involve receptor phosphorylation, G-protein 
uncoupling, internalization, and ultimately intracellular downregulation (Ferguson, 
2001); (Claing et al., 2002); (Mundell et al., 2004). The metabotropic glutamate receptor 
family provides a mechanism by which activation by glutamate can regulate a number of 
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important neuronal and glial functions that are not typically modulated by ligand-gated 
ion channels (Conn, 2003). 
At least two families contributed to the desensitization of the G-protein coupled 
receptors (GPCRs), second messenger-dependent protein kinases and GPCR-specific G-
protein-coupled receptor kinases (GRKs). It has been shown that within seconds of 
receptor stimulation these kinases phosphorylated serine and threonine residues within 
the GPCR intracellular domain, uncoupling receptors from the heterotrimeric G-protein 
(Ferguson, 2001); (Ferguson et al., 1996); (Premont et al., 1995); (Krupnick and Benovic, 
1998). 
We attempted to prove that TRH could modulate levels of Gαq/11 in a complex 
neuronal milieu, in vitro, as will be described. 
 
2. Group I (mGluR1, 5) Receptors 
 
As described previously, the mGluRs have been grouped on the basis of their 
sequence homology, transduction mechanisms, and agonist selectivity. Regarding 
distribution of mGluRs in the rat hippocampus, principal cells of all hippocampal 
subfields were found to be immunoreactive for mGluR5 by Lujan and colleagues, which 
was in agreement with the expression of mRNA previously described by Abe, et al.  
(Lujan et al., 1996); (Abe et al., 1992). Additionally, Lujan found that immunolabeling 
for mGluR1 of granule cells in the dentate gyrus and pyramidal cells of the CA3 but not 
the CA1 area was in agreement with the in situ hybridization results of Shigemoto earlier 
(Lujan et al., 1996); (Shigemoto et al., 1993). These results led Lujan to conclude that 
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most CA3 pyramidal and granule cells express both receptors coupled to PLC; whereas, 
CA1 pyramidal cells only express mGluR5 (Lujan et al., 1996). 
Frauli and colleagues have reported that, of the twenty known classical L-amino 
acids, only glutamate itself directly activates metabotropic glutamate receptors. They 
showed that the effects of other amino acids, namely cysteine, aspartate, and asparagines, 
are due to an indirect action involving glutamate transporters/exchangers, rather than 
direct activation of the receptors (Frauli et al., 2006). 
Frauli demonstrated that glutamate transporter systems allow mGluRs to “sense” 
large increases in the extracellular concentration of certain amino acids (Frauli et al., 
2006). Additionally, Mundell and colleagues have demonstrated the heterologous 
desensitization of metabotropic glutamate receptor splice variants mGluR1a and mGluR1b 
after activation of endogenous Gq/11-coupled receptors in human embryonic kidney 
(HEK293) cells (Mundell et al., 2004); (Mundell and Benovic, 2000). 
Mailleux and colleagues reported the cellular distribution of G proteins Gα and 
G11α by immunocytochemistry in 1992 by using an antipeptide antiserum directed against 
the C-terminal decapeptide conserved between the two G-proteins, and showed by 
Western blot that the brain neuronal localization of Gα and G11α match that of 
phospholipase-C (PLC), as well as 1,4,5-triphosphate receptor and 1,4,5-triphosphate-3-
kinase (Mailleux et al., 1993); (Mailleux et al., 1992). 
Upon guanine nucleotide-binding regulatory protein-mediated activation of PLC, 
phosphatidyl inositol 4,5-bisphosphate (PIP2) is converted into two second-messengers, 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). The immunoreactivity was 
found in neurons where the G-proteins were enriched, at the periphery of the perikarya 
 
 
56 
and in the dendrites. In the hippocampus, after selective lesioning of the pyramidal cells 
with quinolinic acid, a disappearance of staining in the CA1 layer was noted (Mailleux et 
al., 1992). 
Blaabjerg and colleagues actually showed that treatment with the DHPG protects 
neurons from NMDA-induced excitotoxicity in a concentration-dependent manner 
(Blaabjerg et al., 2003), but the  neuroprotection occurred after the initial prolonged 
exposure to the agonist, and was associated with inhibition of the NMDA receptor-
mediated inward current. In addition to changes in Ca2+ homeostasis, production of 
second-messengers IP3 and DAG and activation of protein kinase C (PKC) are associated 
with mGluR activation (Meldrum, 2000). Additionally, it has been shown that group I 
mGluRs can have effects at the gene level (Mao and Wang, 2003). 
Blaabjerg used the cDNA microarray technique to determine whether changes in 
gene expression may be involved in regulation of the group I mGluR-induced 
neuroprotection, and compared gene expression patterns in DHPG-treated organotypic 
hippocampal slice cultures with untreated control cultures. Blaabjerg states that it is 
possible that DHPG-induced increase in certain proteins may lead to internalization of 
NMDA and AMPA receptors, and that internalization has been reported to occur in 
primary hippocampal cultures treated with DHPG (Snyder et al., 2001) and might explain 
the neuroprotection and reduction of NMDA-mediated currents after DHPG treatment. 
Blaabjerg concluded that neuroprotection by group I mGluR activation may not 
be restricted to a single pathway, but may involve multiple mechanisms acting together 
(Blaabjerg et al., 2003). In contrast to the technique Blaabjerg used, exposing 
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hippocampal slice cultures to DHPG for 2 hrs prior to exposure to NMDA, we exposed 
hippocampal slices simultaneously to DHPG + NMDA, which was found to be toxic in 
the slice system, as will be described in sections that follow. 
 
F.  Molecular Markers 
 
1. Caspase-3 
 
Caspase-3 activation is involved in cell death in hippocampal mixed neuronal 
cultures treated with glutamate. Caspase-3 (also referred to as Cpp32, Yama, and 
apopain) is one of the critical enzymes of apoptosis, and is thus the most studied of 
mammalian caspases. Caspase-3 is a member of the CED-3 subfamily, and can activate 
pro-caspases 2, 6, 7, and 9, and specifically cleave most caspase substrates, which have 
been described. 
In addition, caspase-3 plays a central role in mediating chromatin condensation 
and DNA fragmentation, as well as cell blebbing (Nicholson and Thornberry, 1997); 
(Kamada et al., 2005); (Cohen, 1997); (Porter et al., 1997); (Porter and Janicke, 1999). 
Brecht and colleagues demonstrated activation of caspase-3 and DNA 
fragmentation after glutamate toxicity in cultured primary hippocampal neurons, in a 
dose-dependent and time-dependent manner. In the same cultures, caspase-3 was absent 
in astrocytes. Additionally, hippocampal neurons displayed an individual vulnerability to 
glutamate, in that CA1 neurons were more sensitive than CA2/4 or dentate gyrus 
neurons. Neurons in close proximity to astrocytes tolerated glutamate better than neurons 
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without nearby astrocytes (Brecht et al., 2001). We used caspase-3 as a cellular marker 
for apoptotic death in hippocampal neuronal cultures. 
 
2. Secreted Amyloid Precursor Protein (sAPP) Alpha 
 
The toxicity of Aß is strongly enhanced by conditions found during ischemic 
brain injury, such as raised concentrations of EAA and hypoglycemia. It may be 
speculated that the pathology of Alzheimer’s disease is related to a prolonged, chronic 
form of excitotoxicity following the conversion of APP to Aß. Accordingly, the 
unprocessed APP protein seems to have a dampening effect on intracellular calcium 
concentration, by opening neuronal potassium channels, which results in 
hyperpolarization. In agreement with these findings, soluble APP protects neurons from 
Aß toxicity. The 22C11 antibody is used to detect sAPP as described in the sections that 
follow (Leist and Nicotera, 1998a). 
A currently favored hypothesis is that the amyloid beta peptide (Aß), synthesized 
as the larger beta-amyloid precursor protein (APP), is the trigger that induces a cascade 
of events leading to the loss of cholinergic neurons and the progressive dementia that 
defines Alzheimer's disease (AD). One of therapeutic aims in AD is to reduce levels of 
toxic Aß. Cholinergic agonists lower Aß levels and increase the levels of APP processed 
by alternate alpha-secretase pathways (sAPPα). Since cholinesterase inhibitors (ChE-Is) 
are the only approved FDA therapeutics for AD, the effects of ChE-Is on levels of 
secreted APP and Aß were examined during the preparation of this thesis. 
Experiments on primary rat fetal cortical neuronal cells indicated that ChE-Is 
might affect APP processing in multiple ways, as follows. First, drugs like phenserine 
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lowered sAPP and Aß levels in the neuronal cells. Second, agents like galantamine 
showed a trend towards an increase in sAPPα without changing Aß levels. Third, drugs 
like donepezil insignificantly affected sAPPα but reduced Aß levels. 
Characterization of these drugs' actions on APP synthesis and Aß biogenesis 
demonstrates the amyloid-modifying properties of specific anticholinesterases. Drug 
doses tested to achieve APP inhibition were higher than cholinesterase-inhibition but still 
non-toxic. It is possible that treatment with drugs such as those listed may not only treat 
the symptoms of AD, but may perhaps slow disease progression by reducing Aß levels. 
We found that the administration of TRH to cells and slices treated with various 
cholinesterase inhibitors did not significantly affect the levels of sAPP. These 
experiments are further described in the sections that follow. 
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II. HYPOTHESES 
 
The hypotheses to be tested are: 1) TRH protects against glutamate-induced 
toxicity in vitro; and 2) TRH signaling is selectively downregulated as part of this 
neuroprotective mechanism. 
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III. EXPERIMENTAL DESIGN 
 
A. Rationale for using GH-3 Cells in Neuroprotection Studies 
We used pituitary adenoma (GH-3) cells as the first system in which the 
hypothesized neuroprotective effect of TRH was investigated, due to their reported TRH 
receptor profiles (de la Pena et al., 1992). The vast majority of receptors on GH-3 cells 
are, in fact, well characterized, although the presence of mGluRs is controversial. 
Administration of glutamate has been shown to stimulate pituitary hormone secretion. 
This effect was thought to depend on action at a central site in the brain but, alternatively, 
it could also result from a direct action on the pituitary. 
It has been reported that addition of glutamate to rat pituitary cells in primary 
culture is able to induce secretion of prolactin. Recent studies have shown that glutamate 
stimulates calcium entry through L-type calcium channels, and that this effect is 
secondary to membrane depolarization induced by electrogenic uptake through a NAP-
dependent high-affinity glutamate transporter present in GH3 cells (Villalobos et al., 
1996). 
The goal of this portion of the study was to determine if TRH could affect cell 
survival when added to cultured GH-3 cells either prior to, during, or after glutamate-
induced toxicity. GH-3 cells were examined due to their known concentration of TRH 
receptors and less-characterized glutamate receptor population. TRH has been shown to 
activate calcium efflux in GH-3 cells (Nelson and Hinkle, 1994); (Drummond et al., 
1989); (Gershengorn et al., 1983). 
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Renaud and colleagues showed an inhibition by TRH of glutamate-stimulated 
activity in a neuronal cell system (Renaud et al., 1979), and Koenig and colleagues 
showed that TRH inhibited glutamate-stimulated calcium uptake in cortical cells (Koenig 
et al., 1996). Thus, these experiments were designed to determine if TRH added to GH-3 
cell culture systems would exhibit a protective role against glutamate-induced 
excitotoxicity. If it did so, it may involve modulation of glutamate-mediated ionic and/or 
secondary events.  The neuroprotective effect of TRH in neuronal systems, using cultured 
fetal neurons (E17) will also be addressed. 
It has been shown that glutamate is a potent neurotoxin in cell culture (Choi et al., 
1987b), and that TRH stimulates the hydrolysis of phosphatidylinositol 4,5-bisphosphate 
(PIP2) in GH-3 cell membranes. Notably, the stimulation of the phosphoinositide-
phospholipase C (PI-PLC) activity can be blocked by incubation of GH-3 membranes 
with polyclonal antibodies directed against a peptide derived from the C-terminal region 
of Gαq and Gα. This suggested that the TRH-dependent stimulation of PI-PLC in GH-3 
cells is mediated through the G-protein alpha subunits, Gαq and/or Gα11 (Aragay et al., 
1992). 
In GH-3 rat pituitary cells, it has been shown that exposure of GH-3 cells to TRH 
resulted in a marked down-regulation of Gqα/G11α. In GH3 cells, both Gqα and G11α, 
which are expressed at similar levels, were observed to be down-regulated equivalently 
by treatment with TRH (Kim et al., 1994). In other experiments, as described, prolonged 
exposure to TRH resulted in selective and substantial redistribution and down-regulation 
of Gαq/11 when the TRH receptor (TRH-R1) and Gαq/11 are over-expressed in HEK 293 
cells (Svoboda and Milligan, 1994). 
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It has been noted that glutamate increases Ca2+ via the action of glutamate 
transporters in GH-3 cells (Villalobos et al., 2002); (Villalobos and Garcia-Sancho, 
1995). Additionally, Kim and colleagues showed that stimulation of human embryonic 
kidney cells, which expressed the TRH receptor after transfection with TRH-R cDNA 
(HEK-293), and stimulation of GH-3 cells by TRH caused downregulation of Gαq and 
Gα11 proteins. This was extremely important, as we addressed the possible mechanism of 
TRH action in GH-3 cells (Kim et al., 1994). 
In this study, it was to be determined whether TRH can affect cell survival when 
added in cultured cells either prior to, during, or after 8 hrs of 100 nM glutamate-induced 
toxicity. The cells used were pituitary adenoma (GH-3) cells (3 x 106/plate) in six 
separate experiments. Cell viability and integrity were assessed by trypan blue exclusion 
assay and LDH release. 
 
1. Effect of TRH against Glutamate-Induced Toxicity in GH-3 Cells 
 
a. Effect of TRH on GH-3 Cell Viability 
Initially, it needed to be shown that TRH was non-toxic against GH-3 cells, for 
the dose utilized, as well as for the time required for the experiment. 
 
b. Dose Effect of Glutamate on GH-3 Cell Viability 
A toxic dose of glutamate needed to be utilized in the GH-3 cell experiments, and 
a dose response curve needed to be generated, in order to determine the LD50, at which 
dose and time 50% of the GH-3 cells were dead and/or damaged, as assayed by LDH 
analysis and trypan blue exclusion assay. 
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c. Effect of TRH Before Glutamate Toxicity in GH-3 Cells 
After the LD50 of glutamate in GH-3 cells was determined, we treated the GH-3 
cells with TRH before the cells were exposed to 30 minutes of toxic glutamate, in order 
to determine if TRH could exert a prophylactic neuroprotective effect against excitatory 
amino acid-induced toxicity. 
 
d. Effect of TRH During Glutamate Toxicity in GH-3 Cell 
Using the LD50 of glutamate in GH-3 cells, we treated the GH-3 cells with TRH 
during the period when the cells were exposed to 30 minutes of toxic glutamate, in order 
to determine if TRH could exert a neuroprotective effect against excitatory amino acid-
induced toxicity simultaneously with the toxic insult. 
 
e. Effect of TRH After Glutamate Toxicity in GH-3 Cells 
Again using the LD50 of glutamate in GH-3 cells, we treated the GH-3 cells with 
TRH after the cells were exposed to 30 minutes of toxic glutamate, in order to determine 
if TRH could rescue the cells from excitatory amino acid-induced toxicity. 
 
f. Effect of Sustained Release TRH Formulation on Glutamate 
Toxicity in GH-3 Cells 
 
We used TRH nanoparticles in GH-3 cells to analyze another method of delivery 
of TRH within the brain in order to determine whether TRH could protect against 
glutamate-induced toxicity. 
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B. Rationale for using PC12 Cells in Neuroprotection Studies 
We used neuron-like pheochromacytoma (PC12) cells as a negative control in the 
experimental design due to their known glutamate receptor profile and their 
uncharacterized TRH receptor population.  Glutamate treatment of PC12 cells has been 
shown to result in the accumulation of inositol phosphates, suggesting that group I 
metabotropic glutamate receptors (mGluR1 and mGluR5) are present, positively coupled 
to phospholipase C (Kane et al., 1998). Additionally, PC12 survival through a possible 
mechanism of glutamate receptor suppression has been noted (Uemura et al., 2003). 
 In this study, it was to be determined whether TRH can affect cell survival when 
added in cultured cells either prior to, during, or after 8hrs of 100 nM glutamate-induced 
toxicity. The cells used were neuron-like pheochromocytoma (PC12) cells (3 x 106/plate) 
in six separate experiments. Cell viability and integrity were assessed by trypan blue 
exclusion assay and LDH release. 
 
1. Effect of TRH on Glutamate-Induced Toxicity in PC12 Cells 
 
a. Dose Effect of TRH on PC12 Cell Viability 
 
 Initially, it needed to be shown that TRH was non-toxic against PC12 cells, for 
the dose utilized, as well as for the time required for the experiment. 
 
b. Dose Effect of Glutamate on PC12 Cell Viability 
A toxic dose of glutamate needed to be utilized in the PC12 cell experiments, and 
a dose response curve was generated, in order to determine the LD50, at which dose and 
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time 50% of the PC12 cells were dead and/or damaged, as assayed by LDH analysis and 
trypan blue exclusion assay. 
 
c. Effect of TRH Before Glutamate Toxicity in PC12 Cells 
 
After the LD50 of glutamate in PC12 cells was determined, we treated the cells 
with TRH before the cells were exposed to 30 minutes of toxic glutamate, in order to 
determine if TRH could exert a prophylactic neuroprotective effect against excitatory 
amino acid-induced toxicity in PC12 cells, despite the fact that PC12 cells are not known 
to have TRH receptors. 
 
d. Effect of TRH During Glutamate Toxicity in PC12 Cells 
Using the LD50 of glutamate in PC12 cells, we treated the cells with TRH during 
the period when the cells were exposed to 30 minutes of toxic glutamate, in order to 
determine if TRH could exert a neuroprotective effect against excitatory amino acid-
induced toxicity simultaneously with the toxic insult, again despite the fact that PC12 
cells are not known to have TRH receptors. 
 
e. Effect of TRH After Glutamate Toxicity in PC12 Cells 
Again using the LD50 of glutamate in PC12 cells, we treated the cells with TRH 
after the cells were exposed to 30 minutes of toxic glutamate, in order to determine if 
TRH could rescue the cells from excitatory amino acid-induced toxicity, despite the fact 
that PC12 cells are not known to have TRH receptors. 
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C. Rationale for using Hippocampal Slices and Anterior Pituitaries in 
Neuroprotection Studies 
 
We used hippocampal slices in order to increase the complexity of the 
experimental design, and to get closer to the cellular environment, which would be 
encountered in vivo.  CNS slice preparations have become very useful in studying 
numerous scientific questions. 
In particular, hippocampal slice studies have been used to define the role of 
excitatory amino acids and their derivatives in the induction of, or the protection against, 
neuronal damage (Schurr et al., 1984); (Schurr et al., 1995), although we are among the 
first to maintain hippocampal slices for an extended period of time (15 hrs). Schurr and 
colleagues demonstrated that rat hippocampal slices, which are sensitive and inexpensive, 
are very well suited as an in vitro system for use in the screening of both agonists and 
antagonists of excitatory amino acid receptors (Schurr et al., 1995). 
The hippocampal slices were used due both to the presence of neurons with the 
required receptor profiles, as well as the presence of glia, thus increasing the complexity 
of the experimental design, and therefore reflecting the complexity of the neuronal 
environment, which exists in vivo. 
Pitfalls of the slice superfusion have been described as well (Reid et al., 1988), 
including possible problems due to the thickness of the slices in the experimental design, 
and viability of the slices over the course of the experiment, as well as the fact that the 
superfusion medium must be tightly controlled by the experimental design. In this 
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system, the goal was to determine if TRH can protect against glutamate excitotoxicity in 
superfused hippocampal slice or anterior pituitary preparations. 
Rat dentate gyrus slices were prepared according to previously described methods 
(Low et al., 1989a); (Knoblach et al., 1989), and were used to determine if prolonged 
exposure to TRH or its analogues resulted in specific downregulation of Gαq/11. If so, this 
would demonstrate that TRH can modulate levels of Gαq/11 in a complex neuronal milieu 
in vitro (Reid et al., 1988); (Schoepp and Desai, 1995); (Schurr et al., 1984); (Schurr et 
al., 1985); (Schurr et al., 1987). 
We used anterior pituitaries in the superfusion studies as a positive control in the 
slice superfusion studies, due to the presence of a high density of known TRH receptors 
(Schally and Arimura, 1977); (Schally and Bowers, 1 A.D.); (Nillni and Sevarino, 1999). 
The granule cells of the hippocampal dentate gyrus (DG) were examined, since they 
possess both metabotropic glutamate receptors (mGluRs) and TRH receptors, all of 
which utilize Gαq/11 in their second messenger signal cascade post-synaptically (Heuer et 
al., 2000); (Gershengorn and Osman, 1996); (Calza et al., 1992); (Cao et al., 1998); 
(Itadani et al., 1998); (Sun et al., 2003). 
Anterior pituitaries were also used as a positive control due to the fact that the 
downregulation of Gαq/11 in the pituitary after TRH administration has been demonstrated 
(Hinkle, 1989). Glutamate has been shown to induce pituitary hormones in vivo (Terry et 
al., 1985); (Mason et al., 1988). 
Another key reason that we used slices and pituitaries was to be able to examine 
the tissue using morphological analysis, comparing damaged tissue with undamaged 
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tissue, and then verifying those results with Western blots, which would be used to 
further elucidate the hypothesized mechanism of neuroprotection in the experimental 
design. 
TRH administration has been shown to induce the sub-cellular redistribution and 
down-regulation of its intracellular signaling protein, Gαq/11. TRH added to anterior 
pituitary cells that were co-transfected with G-protein and the TRH receptor resulted in 
substantial redistribution and reduction in the total cellular levels of this G-protein in 
response to activation of phospholipase-C (PLC)-coupled receptor (Milligan et al., 1993); 
(Svoboda et al., 1996). Furthermore, TRH levels are markedly increased and TRH 
receptors significantly downregulated after kindled seizures  (Kubek et al., 1993). 
 
1. Effect of Superfusion Time on Slice Viability 
 
a. Assessment by LDH Assay 
It was essential to determine that slices and whole pituitaries would be viable for 
the entire period of the superfusion experiments, in order to be able to accurately assess 
the neuroprotective effect of TRH and its analogues against excitatory amino acid-
induced toxicity. The analysis of LDH release into the superfusate, collected at specific 
time points, allowed us to determine if and when cells were experiencing membrane 
damage. 
 
b. Assessment by Morphology 
It was also essential to determine visually that slices and whole pituitaries would 
be viable for the entire period of the superfusion experiments, in order to be able to 
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accurately assess the neuroprotective effect of TRH and its analogues against excitatory 
amino acid-induced toxicity. The morphological analysis of the slices, collected at 
specific time points, and examined microscopically, allowed us to determine visually if 
the tissue was experiencing swelling and/or shrinkage over time and/or with various 
drugs. 
 
c. Assessment by Caspase-3 Assay 
Caspase-3 assays were conducted on the slices and anterior pituitaries as another 
way to determine that slices and whole pituitaries were (or were not) viable for the entire 
period of the superfusion experiments, in order to be able to accurately assess the 
neuroprotective effect of TRH and its analogues against excitatory amino acid-induced 
toxicity. The enzymatic analysis of the slices, collected at specific time points, and 
compared to negative and positive superfusion slice controls, allowed us to determine if 
the tissue was experiencing apoptotic damage over time and/or with various drugs. 
 
2. Effect of TRH on Glutamate Toxicity in the Anterior Pituitary and in 
Hippocampal Slices 
 
a. Dose Effect of N-Methyl-D-Aspartic Acid (NMDA) on 
Superfused Hippocampal Slice Viability 
 
We over-stimulated hippocampal tissue slices with N-methyl-D-aspartate 
(NMDA), a selective ionotropic glutamate receptor agonist, in order to cause damage to 
the hippocampal slices. 
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b. Dose Effect of NMDA + (S)-3,5-Dihydroxyphenylglycine (S-
DHPG) on Superfused Hippocampal Slice Viability 
 
We also over-stimulated tissue slices with a combination of N-methyl-D-aspartate 
(NMDA), a selective ionotropic glutamate receptor agonist, and with 
dihydroxyphenylglycine (DHPG), a selective group I metabotropic glutamate receptor 
agonist, and with a combination of both, in order to cause damage to the hippocampal 
slices. 
 
c. Effect of TRH on Superfused Hippocampal Slice Viability after 
Exposure to Toxic Dose of NMDA + DHPG 
 
TRH and its analogues were added during the exposure of superfused 
hippocampal slices to toxic NMDA and DHPG doses to determine its neuroprotective 
effects in the slice system. 
 
d. Effect of TRH on Levels of Secreted Amyloid Precursor 
Protein (sAPP) in Superfused Hippocampal Slices 
 
Alzheimer’s disease (AD) is characterized by the significant loss of cholinergic 
markers and depositions of the amyloid-beta peptide (Aß), which is derived from the Aß 
precursor protein (APP). Currently, acetylcholinesterase inhibitors and memantine are the 
FDA-approved drugs but they are used only for symptomatic relief. 
The aim of this investigation was to study the effect of a highly selective 
acetylcholinesterase inhibitor drug, phenserine, on the level of the beta-amyloid precursor 
protein (APP) in whole hippocampal slices following superfusion. Utilizing whole 
hippocampi serially sectioned from Sprague-Dawley rats, the effects of varying doses of 
phenserine (1, 3 and 10 µm) on secreted APP (sAPP) were investigated 
 
 
72 
 
e. Effect of TRH on Superfused Anterior Pituitary Viability 
 
Initially, it needed to be shown that TRH was non-toxic against anterior 
pituitaries, for the dose utilized, as well as for the time required for the experiment. 
 
 
f. Effect of TRH on DHPG/NMDA-Treated Superfused 
Hippocampal Slices 
 
Using toxic dose of DHPG + NMDA in hippocampal slices, we treated the slices 
with TRH during the period when the cells were exposed to a toxic dose of DHPG + 
NMDA, in order to determine if TRH could exert a neuroprotective effect against 
excitatory amino acid-induced toxicity simultaneously with the toxic insult. 
 
g. Effect of TRH on Gαq/11 Levels in Hippocampal Dentate Gyrus 
Slices 
 
We focused on heterologous receptor down regulation as a mechanism, which 
may be responsible for the neuroprotective effect of TRH noted in our slice studies. 
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IV. MATERIALS and METHODS 
 
A. Hippocampal Subregional Dissection 
 
The procedure previously described by Low, and used in the Kubek lab was 
utilized for the hippocampal slice superfusion experiments (Low et al., 1989b). Rats were 
decapitated, and hippocampi were removed from the brain, keeping the dorsal (septal), 
ventral (temporal) orientation intact, and placed on an ice-cold aluminum plate. The 
dissection of the hippocampi started with a slice transversely through the center, 
separating them into two halves. Transverse sections of 500 µm were obtained, using 
microforceps and a scalpel with a stainless steel #5100 eye blade (George Tiemann, 
Philadelphia, PA). 
Hippocampal structures were identified using a low-power dissecting microscope, 
with the dentate gyrus as the key feature. The first cut was made at 90 degrees to the ends 
of the dentate gyrus, and the next cut (a continuation of cut 1) was made parallel to, and 
immediately outside this region. This isolated the CA3 subregion of Ammon’s Horn, as 
described in the Kubek lab previously. 
Next, cuts 2 and 3 were made inside the cell bodies of the granule layer, isolating 
CA4 of Ammon’s Horn, as well as the hilar region of the dentate gyrus. Cut 4 was then 
made along the fissure between the dentate gyrus and Ammon’s Horn, in order to isolate 
the dentate gyrus for superfusion. 
The final cut was then made through the arc of Ammon’s Horn, at the transition 
point between CA1 and the subiculum. Microforceps were used to place the dentate gyrus 
subregions on tared tin foil squares measuring 2 inches x 2 inches, weights were 
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obtained, and the subregions were then subjected to superfusion. It should be noted that 
tissue was manipulated as minimally as possible prior to superfusion, and that the 
dissection did not take longer than 30 min to complete for 2 animals, since TRH has been 
shown to be stable for at least 2 hours (Kubek et al., 1977). 
Furthermore, the tissue obtained from the superfusion wells after the superfusion 
procedure was complete was separated into sections to be (1) frozen at -70°C for future 
Western blotting; (2) frozen at -20°C for LDH assay; or (3) fixed in 10% 
paraformaldehdye for morphological analysis via cresyl violet staining, as described. 
 
B. Superfusion of Hippocampal Slices 
The ability to maintain viable brain slices over an extended period of time is 
essential for several molecular and morphological analyses, which require tissue to be 
viable for hours or even days. We began with the hypothesis that rat hippocampal slices 
could be maintained for more than the 12-16 hours previously described. 
We measured the viability of superfused and non-superfused hippocampal slices 
for a period of 60 hours via (1) lactic dehydrogenase (LDH) release assays, as a measure 
of cell damage; (2) caspase-3 assays, as a measure of apoptosis; and (3) Western blots, as 
a measure of protein expression. 
In these hippocampal time course experiments, young adult WISTAR rats (4-5 
weeks old) were sacrificed via live decapitation, and the hippocampi (60-80 mg) were 
removed and dissected on ice into 500µm thin sections, while bathed with cold 0.9% 
normal saline. These thin hippocampal slices were randomized into 4 groups and allowed 
to equilibrate for 2 hours in oxygenated low calcium (1.0 mM) Kreb’s Ringer 
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Bicarbonate buffer, at a pH of 7.4, warmed to 37°C, superfused through the tissue at a 
rate of 0.5 ml/min via a peristaltic pump. 
Next, slices and 2 ml of effluent were collected after 0, 12, 24, 36, 48, and 60 
hours of superfusion at 0.5 ml/min with a continuously oxygenated normal calcium (2.5 
mM) Kreb’s Ringer Bicarbonate buffer, at a physiological pH of 7.4 and a temperature of 
37°C. 
The tissue was immediately frozen in two vials at -70°C, and effluent was placed 
at 4°C, until the assays were performed. Simultaneously, random tissue samples were 
removed after the 2 hours of initial oxygenation in low calcium (Ca++) KRB and placed 
immediately in a non-superfusion environment, at 37°C in normal calcium oxygenated 
buffer. These non-superfused slices and 2 ml of KRB were also collected after 0, 12, 24, 
36, 48, and 60 hours of incubation. Slices were immediately frozen at -70°C, and media 
was placed at 4°C until the assays were performed. 
Rat dentate gyrus slices (500 µm) or anterior pituitaries were equilibrated for 2 
hours in low Ca++ (1.0 mM) KRB, then superfused for 12 hours in either normal Ca++ (2.5 
mM) with 10 µM TRH, 3-Me-His-TRH, or Free Acid-TRH-containing KRB. 
The DG slices were equilibrated in low Ca++-containing phosphate buffer (KRB), 
in order to determine baseline LDH release and morphology, and were then superfused 
for various times in either normal Ca++-containing KRB with TRH, or with glutamate 
analogues. 
Tissue slices were over-stimulated with N-methyl-D-aspartate (NMDA), a 
selective ionotropic glutamate receptor agonist, and with dihydroxyphenylglycine 
(DHPG), a selective group I metabotropic glutamate receptor agonist, and with a 
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combination of both, in order to cause damage to the hippocampal slices. TRH and its 
analogues were added during the NMDA and DHPG exposure to determine its 
neuroprotective effects in the slice system. 
LDH in the superfusate were compared to controls over time and treatment. 
Cresyl violet histological stains were conducted to determine qualitatively whether any 
difference exists morphologically between slices superfused over time or with drugs. 
 
C. Cell Culture Technique for GH-3 Cells 
 
Rat pituitary adenoma (GH-3) cells from ATCC were cultured in RPMI 1640 
(Fisher) with 0.5% FBS (Fisher), 15% HS (Fisher) without antibiotic/antimycotic, and 
maintained in a 5% CO2 incubator at 37°C until equal confluence was attained. Culture 
flasks coated with 0.2 mg/ml poly-D-lysine for the initial 7-10 day growth period were 
used. 
Subsequently, cells were harvested using pancreatin digestion, and equal cell 
aliquots were plated at a density of 3 X 106 cells per 60mm Petri dish. A 16-hour cycle of 
treatment with glutamate (glu), TRH, or a combination of glu and TRH was utilized: 8 
hours of treatment in low serum media (LSM), followed by wash with low serum media 
alone, and an additional 8 hours of treatment. 
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The specific protocol for the 16 hours was as follows: 
FIRST EIGHT HOURS 
PLATE 1:  low serum media (LSM) + 100 nM glu (G) 
PLATE 2:  LSM + 100 nM glu (G) 
PLATE 3:  LSM + 100 nM glu + 10 µM TRH (GT) 
PLATE 4:  LSM + 100 nM glu (G) 
PLATE 5:  LSM + 10 µM TRH (T) 
PLATE 6:  LSM + 10 µM TRH (T) 
PLATE 7:  LSM + 10 µM TRH (T) 
PLATE 8:  LSM ONLY (M) 
 
SECOND EIGHT HOURS 
PLATE 1:  LSM + 100 nM glu (G/G) 
PLATE 2:  LSM + 10 µM TRH (G/T) 
PLATE 3:  LSM + 100 nM glu + 10 µM TRH (GT/GT) 
PLATE 4:  LSM ONLY (G/M) 
PLATE 5:  LSM + 100 nM glu (T/G) 
PLATE 6:  LSM + 10 µM TRH (T/T) 
PLATE 7:  LSM ONLY (T/M) 
PLATE 8:  LSM + 100 nM glu (M/G) 
 
At 0, 4, 8, 12, and 16 hours, 50 µl aliquots of conditioned media were collected 
for lactic dehydrogenase (LDH) analysis by a calorimetric tetrazolium dye method 
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(Sigma) to assess cell membrane viability. Cells were harvested on ice after 16 hours, and 
cell counts were performed via Trypan Blue exclusion analysis to determine cell 
viability. 
 
D. Cell Culture Technique for PC12 Cells 
 
Rat neuron-like pheochromacytoma (PC12) cells from ATCC were cultured in 
RPMI 1640 (Fisher) with 0.5% FBS (Fisher), 15% HS (Fisher) without 
antibiotic/antimycotic, and maintained in a 5% CO2 incubator at 37°C until equal 
confluence was attained. Culture flasks coated with 0.2 mg/ml poly-D-lysine for the 
initial 7-10 day growth period were used. 
Subsequently, cells were harvested without digestion, using sterile spatulas, and 
equal cell aliquots were plated at a density of 3 X 106 cells per 60mm Petri dish. A 16-
hour cycle of treatment was utilized: 8 hours of treatment in low serum media, followed 
by wash with low serum media alone, and an additional 8 hours of treatment. 
 
The specific protocol for the PC12 treatments was as follows: 
FIRST EIGHT HOURS 
PLATE 1:  low serum media (LSM) + 100 nM glu (G) 
PLATE 2:  LSM + 100 nM glu (G) 
PLATE 3:  LSM + 100 nM glu + 10 µM TRH (GT) 
PLATE 4:  LSM + 100 nM glu (G) 
PLATE 5:  LSM + 10 µM TRH (T) 
PLATE 6:  LSM + 10 µM TRH (T) 
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PLATE 7:  LSM + 10 µM TRH (T) 
PLATE 8:  LSM ONLY (M) 
 
 
SECOND EIGHT HOURS 
PLATE 1:  LSM + 100 nM glu (G/G) 
PLATE 2:  LSM + 10 µM TRH (G/T) 
PLATE 3:  LSM + 100 nM glu + 10 µM TRH (GT/GT) 
PLATE 4:  LSM ONLY (G/M) 
PLATE 5:  LSM + 100 nM glu (T/G) 
PLATE 6:  LSM + 10 µM TRH (T/T) 
PLATE 7:  LSM ONLY (T/M) 
PLATE 8:  LSM + 100 nM glu (M/G) 
 
At 0, 4, 8, 12, and 16 hours, 50 µl aliquots of conditioned media were collected 
for lactic dehydrogenase (LDH) analysis by a calorimetric tetrazolium dye method 
(Sigma) to assess cell membrane viability. Cells were harvested on ice after 16 hrs, and 
cell counts were performed via Trypan Blue exclusion analysis to determine cell 
viability. 
 
E. Western Blot Analysis 
 
Western blots were performed on the tissue extract as follows:  100 µg of protein 
was aliquoted from each sample extract, and speed vacuumed to dryness. 75 µl of water 
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and 25 µl of 4X Sample Buffer were added to obtain 1.0 µg protein/1.0 µl for each 
sample. Boil for 5 minutes. PAGE in 12% agarose gel was performed using 30 µg of 
protein per well. The gel was run at 200V for 48 minutes. Western blot transfer to 
nitrocellulose membrane was performed via running in transfer buffer at 110V for 60 
minutes. 
Ponceau stain was used to visualize with acetic acid to verify that serum protein 
transfer occurred in equal amounts per well. Blot photographs were made using the GDS 
system. Ponceau was washed with TBST buffer for 10 minutes x 3, and nonspecific 
binding was blocked with 3% gelatin incubation for 1-2 hours. 
Blots were washed with TBST for 10 minutes x 3, and probed O/N with primary 
antibody of choice. The blots were rinsed with TBST for 10 minutes x 3, and were 
hybridized with secondary antibody for 1-2 hours. Blot was rinsed with TBST buffer for 
10 minutes x 2 and with TBS buffer for 10 minutes x 1. 
Next, biotinylated avidin (VECTASTAIN kit) was added for 1 hour. Blot was 
rinsed with TBS buffer for 10 minutes x 3, and developed with horseradish peroxidase. 
Finally, densitometric analyses of Western Blots with Scion Image program were 
performed. 
We used the Western blot technique described by Mallieux and colleagues 
(Mailleux et al., 1992)  to determine the effect of TRH administration on the levels of G-
proteins Gqα /G11α, using hippocampal slice homogenates and antiserum against the G-
proteins. A linear range of G-protein immunoreactivity was used as a standard against 
which the actual amount of G-protein present in the hippocampal homogenate could be 
determined. 
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F. LDH Assay 
 
The toxic effects of unknown compounds have been measured in vitro by 
counting viable cells after staining with a vital dye. Other methods that have been used 
include the measurement of DNA synthesis by radioisotope incorporation, cell counting 
by automated counters, and other methods relying on various dyes and cellular activity. 
The lactate dehydrogenase (LDH) assay (Sigma) is a means of measuring either the 
number of cells via total cytoplasmic LDH, or of membrane integrity as a function of the 
amount of cytoplasmic LDH released into the medium (Sigma). 
In this study, the latter measurement is that of membrane integrity as a function of 
the amount of cytoplasmic LDH released into the medium, whether it is the effluent in a 
slice superfusion study or the conditioned low serum medium (LSM) used in cell 
experiments, was utilized (Koh and Choi, 1987). 
The LDH assay is reported to be simple and accurate, yielding reproducible 
results. The LDH assay is based on the reduction of NAD by the action of LDH. The 
resulting reduced NAD (NADH) is then utilized in the stoichiometric conversion of 
tetrazolium dye. The resulting colored compound is then measured via 
spectrophotometric analysis at an absorption wavelength of 490 nanometers, using a 
spectrophotometer (Beckman/Coulter). 
If the cells are lysed prior to assaying the medium, an increase or decrease in cell 
numbers results in a concomitant change in the amount of substrate converted (Sigma).  
This indicates the degree of inhibition of cell growth (cytotoxicity) caused by the test 
material. If cell-free aliquots of medium from cultures, which have been exposed to 
different treatments, are assayed as in this study, then the amount of LDH activity can be 
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used as an indicator of relative cell viability as well as a function of membrane integrity 
(Decker and Lohmann-Matthes, 1988); (Legrand et al., 1992); (Sigma Product Info, 
TOX-7). 
LDH assays were performed on both superfused and non-superfused samples, as 
follows. For the effluent/KRB samples, triple 45 µl aliquots of effluent were incubated 
for 30 minutes with 5 µl of water and 25 µl of a Master Mix (SIGMA TOX-7 LDH 
ASSAY) containing LDH dye, LDH substrate, and LDH enzyme in darkness, using a 96-
well multiplate. Absorbance of each sample was read using a microplate reader at 490 
nm. For the tissue samples, tissue extract was obtained via placing the superfused tissue 
in 200 µl of ice cold IP Buffer (protease inhibitor), and homogenizing with a Polytron 
homogenizer at 50% speed for 10 seconds. The homogenate was cold centrifuged for 15 
minutes at 10,000 rpm, and protein estimation was performed on the homogenate using 
the Bradford method. 
For the extract samples, triple 5 µl aliquots of extract were incubated for 30 
minutes with 5 µl of water and 25 µl of a Master Mix containing LDH dye, LDH 
substrate, and LDH enzyme in darkness, using a 96-well multiplate. Absorbance of each 
sample was read using a microplate reader at 490 nm. LDH values were recorded for 
extract analysis as LDH/µg total protein. 
Several possible sources of error exist. The reconstituted enzyme preparation is 
stable when stored frozen. Storage at 4°C may result in loss of activity and yield 
erroneous results. Additionally, uneven separation of culture fluid in wells of multiwell 
plates may cause erroneous results. Finally, NADH is subject to photodegradation. 
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Excessive exposure of the assay reaction to light can reduce both sensitivity and 
accuracy. 
Standard curves were constructed using LDH enzyme standard (Roche), using 0, 
2, 4, 6, 8, 10, 12, 14, 16, 22, and 24 ng in triplicate. Unknowns were diluted so that 
colorimetric density readings, at specific 490 nm absorbance, were on the linear part of 
the standard curve, and corrected for dilution. 
 
G. Caspase-3 Assay 
Caspase-3 assays were performed as follows. The morning of the assay, slices 
were weighed and homogenized in 200 µl of Promega cell lysis buffer (#G726A, 
composition protected via proprietary rights) using a Polytron tissue homogenizer set at 
50% speed for 10 seconds. The resultant suspension was centrifuged at 11,000 rpm for 20 
minutes, and a protein assay was performed. (Approximately 25-100 µg of total protein is 
used for the assay). 
The assay was then performed in a total volume of 100 µl in 96-well plates. 
Replicate wells were prepared containing blank (no tissue extract, but all other reactants 
added). Replicate wells of samples were prepared by adding 32 µl reaction buffer (312.5 
mM HEPES, 31.25% w/v sucrose, 0.3125% w/v CHAPS), 2 µl of DMSO, 10 µl of 
100mM DTT, and 27 µl of each tissue extract, as well as 27 µl of H2O. Finally, 2 µl of 
the DEVD-pNA Substrate (10 mM stock) was added to all wells (Brecht et al., 2001). 
The plates were incubated for 4 hours at 37°C. (Note that overnight incubation at 
22-25°C is also possible, since sample absorbance should not change, although 
background absorbance may increase). Absorbance was read using a microplate reader at 
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405nm. Note that (1) our absorbance range (corrected for protein) was from 0.087-0.193 
for Time 0 thru 48 hours of superfusion (T-0 thru T-48), and a value of 0.633 at 60 hours; 
and (2) the Promega catalog number used for the caspase assay is #G7220. 
 
H. Trypan Blue Analysis 
Immediately following the harvest of cells (GH-3, PC12, or fetal neurons), 20 µl 
of Trypan Blue solution (Sigma-Aldrich) was added to 20 µl of cellular suspension. Cell 
counting was conducted in a hemacytometer at 20X magnification, using a light 
microscope. Dead cells stained blue, while viable cells maintained a translucent, clear 
appearance, as well as a spherical morphology. Only the viable cells were included in the 
cell count. 
The hemacytometer chamber had a depth of 0.1 mm, and the counting area was 1 
mm2. Thus, the number of cells in suspension was calculated from the number of cells 
counted in 10-4 ml (0.1 mm x 1.0 mm2 = 0.1 mm3 = 10-4 ml). Cell death was calculated 
using the survival percentage of untreated control cells and comparing that figure to the 
survival percentage of treated cells. The resulting equation was: # cells counted/1 x 10-4 
ml x 1 ml suspension = N cells). 
 
I. Morphology 
Morphological analysis of superfused hippocampal slices was performed using 
cresyl violet histological staining. Cresyl violet stain was prepared by mixing 0.5 g cresyl 
violet in 100 ml double distilled water (DDW), and allowing it to “ripen” for 48 hrs prior 
to filtering. A 50/50 mixture of Canada Balsam/xylene was used for the analysis, as well, 
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in a solution consisting of 50 ml Canada Balsam plus 50 ml xylene.  The hippocampal 
slices were fixed in 10% paraformaldehyde and then cut via serial frozen sections on a 
microtome to a thickness of 10 µm. The resultant slices were placed on a microscope 
slide and allowed to dry overnight. The slices were then subjected to the following 
staining protocol, prior to being photographed under a microscope at various 
magnifications. 
 
3 min DDW rinse 
45 sec cresyl violet stain 
1 min DDW rinse 
2 min DDW rinse (fresh) 
1 min 95% ethanol 
1 min 100% ethanol 
1 min xylene 
2 min balsam/xylene 
4 min 100% ethanol (fresh) 
4 min 100% ethanol (fresh) 
5 min xylene (fresh) 
5 min xylene (fresh) 
Permount coverslip added 
Allow to dry horizontally 
Examine microscopically 
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V. RESULTS 
 
A. Effect of TRH on Glutamate-Induced Toxicity in GH-3 Cells 
 
1. Toxic Dose of Glutamate in GH-3 Cells via LDH and Trypan Blue 
Analyses 
 
The LD50 for glutamate in GH-3 cell cultures was found to be 100 nM. These 
results were confirmed via both trypan blue exclusion analysis as well as by LDH assay, 
as a measure of cell viability and cell damage, respectively. 
 
2. Non-Toxicity of TRH in GH-3 Cells via LDH and Trypan Blue 
Analyses 
 
TRH (10µM/8 hrs) treatment was non-toxic by both trypan blue exclusion 
analysis and LDH assay. (Figure 3 shows LDH Assay) This was essential in order to 
show that the cell damage was due to glutamate, and that the resultant neuroprotection 
was due to TRH, although the mechanism for neuroprotective effect was not known until 
further experimentation occurred, as will be addressed in subsequent sections. 
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Figure 3. 
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3. Effect of TRH Before Glutamate Toxicity in GH-3 Cells 
 
TRH pretreatment resulted in a significant reduction (compared to control) in 
GH-3 cells, in cell death (16%, P<0.05, P<0.05) and damage (GH-3: 68%, P<0.05).  
(Figures 4 and 5) 
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Figure 4. 
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Figure 5. 
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4. Effect of TRH During Glutamate Toxicity in GH-3 Cells 
 
TRH treatment during glutamate (glut) toxicity resulted in a reduction in cell 
death (GH-3: 33%, p<0.05, P<0.05) and damage (GH-3: 102%, P<0.05). 
(Figures 6 and 7) 
 
EFFECT OF 8 HRS TRH (X2) DURING GLUTAMATE TOXICITY IN GH-3 
CELLS
0.00
1.00
2.00
3.00
4.00
G-G GT-GT T-T
TREATMENT
M
E
A
N
 V
IA
B
L
E
 C
E
L
L
S
 (
E
+
0
6
)+
/-
S
E
M *
58%
91% 100%
Figure 6. 
 
 
 
91 
 
 Figure 7. 
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5. Effect of TRH After Glutamate Toxicity in GH-3 Cells 
 
TRH given 8hrs after glut insult resulted in cellular rescue in GH-3 (GH-3: 9%, 
P<0.05) and also in damage reduction (GH-3: 44%, P<0.05).  (Figures 8 and 9) 
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Figure 9. 
 
 
 
 
B. Effect of TRH on Glutamate-Induced Toxicity in PC12 Cells 
 
1. Toxic Dose of Glutamate in PC12 Cells via LDH and Trypan Blue 
Analyses 
 
The LD50 for glutamate in PC12 cell cultures was found to be 100 nM. These 
results were confirmed via both trypan blue exclusion analysis as well as by LDH assay, 
as a measure of cell viability and cell damage, respectively. 
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2. Non-Toxicity of TRH in PC12 Cells via LDH and Trypan Blue 
Analyses 
 
TRH (10µM/8 hrs) treatment was non-toxic by both trypan blue exclusion 
analysis and LDH assay. (Figure 10) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. 
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3. Effect of TRH Before Glutamate Toxicity in PC12 Cells 
 
TRH pretreatment resulted in a significant reduction (compared to control) in 
PC12 cells, in cell death (PC12: 21%, P<0.05) and damage (PC12: 11%, p<0.05). 
(Figures 11 and 12) 
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Figure 12. 
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4. Effect of TRH During Glutamate Toxicity in PC12 Cells 
 
TRH treatment during glut toxicity resulted in a reduction in cell death (PC12: 
27%, P<0.05) and damage (PC-12: 10%, p<0.05).  (Figures 13 and 14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. 
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Figure 14. 
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5. Effect of TRH After Glutamate Toxicity in PC12 Cells 
 
TRH given 8 hours after glutamate insult resulted in cellular rescue in PC12 cells, 
(PC12: 15%, P<0.05) but not in damage reduction.  (Figures 15 and 16) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. 
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Figure 16. 
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C. Assessment of Superfusion Time on Hippocampal Slice Viability 
 
1. LDH Assay 
 
Hippocampal slices were superfused with oxygenated normal (2.0 mM) calcium-
containing KRB for 48 hours. Relative LDH release in 50 µl superfusate expressed as OD 
@ 490 nm after 0, 4, 6, 8, 12, 15, 36, and 48 hours. *P<0.05 T-0 versus T-36, T-48 from 
three combined experiments. No significant difference was noted in superfusate at earlier 
time points. 
There was no detectable increase in LDH release from T-0 to T-15 hrs in 
superfused hippocampal slices; however, there was a significant elevation in LDH 
release from superfused hippocampal slices at T-36 and T-48 hrs. (Figure 17) 
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Figure 17. 
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2. Effect of TRH and its Analogs on LDH Release in Superfused Dentate 
Gyrus 
 
DG slices were superfused with KRB (control) or KRB containing 10 µM TRH 
(T10), 10 µM 3-Me-HIS-TRH (M10), or 10 µM Free-Acid-TRH (FA10) for 12 hours. C 
= controls, T10 = TRH 10 µM, M10 = 3-Me-HIS-TRH 10 µM, FA10 = Free-Acid-TRH 
10 µM. As a positive LDH control, slices were exposed to 30 µM NMDA for 12 hours, 
or subjected to freeze-thawing prior to superfusion. Relative LDH release in 50 µl 
superfusate expressed as OD @ 490 nm after 0, 4, 6, 8, 12, and 15 hours. *P<0.05 C 
versus F/T, NMDA from three combined experiments. No significant difference was 
noted in slices treated with T10, M10, or FA10. (Figure 18) 
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Figure 18. 
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3. Caspase-3 Assay 
 
Hippocampal slices were superfused with oxygenated normal KRB for 60 hours. 
A small increase of caspase activity occurred over time with a substantial increase after 
48 hours of superfusion. Relative caspase-3 activity/µg protein of tissue lysate expressed 
as OD @ 405 nm after 0, 12, 24, 36, 48, and 60 hours. *P<0.05 T-0 versus T-48 & 60 (N 
= 4). (Figure 19) 
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Figure 19. 
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D. Effect of TRH on Glutamate-Induced Toxicity in the Anterior Pituitary and 
Hippocampal Slices 
 
1. Effect of NMDA in Superfused Hippocampal Slices 
Our preliminary results show that a 30-minute exposure of superfused 
hippocampal slices or anterior pituitaries to 30 µM NMDA, followed by 12 hours of 
superfusion, caused significant damage demonstrated both morphologically and by LDH 
release assays, versus untreated controls. 
 
2. Effect of NMDA + DHPG in Superfused Hippocampal Slices 
Our preliminary results show that a 30-minute exposure to a combination of 10 
µM DHPG / 30 µM NMDA, 100 µM DHPG / 30 µM NMDA, and to either 10 µM 
DHPG or 30 µM NMDA alone, caused significant damage, demonstrated by 
morphological analyses and LDH release assays, after 12 hours of superfusion. 
Interestingly, 30-minute exposure to a combination of 5 µM DHPG / 30 µM 
NMDA, followed by 12 hours of superfusion resulted in significantly less damage than 
that seen in the slices exposed to toxic doses of DHPG + NMDA. Future studies will 
examine the neuroprotective effect of TRH against hippocampal slices or anterior 
pituitaries damaged by toxic doses of DHPG + NMDA. 
 
3. Effect of TRH on Levels of sAPP in Superfused Hippocampal Slices 
 
The hippocampal sections were bathed in a superfusion buffer of oxygenated low 
calcium KRB for 2 hours to allow LDH to stabilize, and then were superfused in an 
oxygenated normal calcium buffer with varying concentrations of phenserine for 8 and 15 
hours. 
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Effluent samples were collected at times 0, 4, and 8 hours for the 8-hour 
experiment, and at times 0, 8, and 15 hours for the 15-hour experiment, to verify that cell 
death was not occurring. The slices were collected at the endpoint, homogenized in 300 
µl IP buffer and 40 µg of each sample was loaded onto a 12% PAGE for Western blotting 
analysis with 22C11. (Figure 20) 
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Figure 20. 
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4. Effect of TRH on Superfused Hippocampal Slices 
 
Rat dentate gyrus slices (500 µm) were equilibrated for 2 hours in low Ca++ (1.0 
mM) KRB, then superfused for 12 hours in either normal Ca++ (2.5 mM) with 10 µM 
TRH, 3-Me-His-TRH, or Free-Acid-TRH-containing KRB. LDH in the superfusate was 
not significantly different from controls over time or treatment. Morphology via cresyl 
violet staining revealed no apparent difference between slices superfused over time or 
with drugs. 
 
5. Effect of TRH on Superfused Anterior Pituitaries 
 
Rat anterior pituitaries were equilibrated for 2 hours in low Ca++ (1.0 mM) KRB, 
then superfused for 12 hours in either normal Ca++ (2.5 mM) with 10 µM TRH, 3-Me-
His-TRH, or Free-Acid-TRH-containing KRB. LDH in the superfusate was not 
significantly different from controls over time or treatment. Morphology via cresyl violet 
staining revealed no apparent difference between slices superfused over time or with 
drugs. 
 
a. Figures 21 and 22 demonstrate that prolonged superfusion (12 hrs) of 
dentate gyrus slices with 10 µM TRH or 10 µM 3-Me-His-TRH (3-Me-
HTRH) significantly reduced Gαq/11 levels by 79% and 93%, respectively. 
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Figure 21. 
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  Figure 23. 
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b. Figures 24 and 25 show that prolonged superfusion (12 hours) of anterior 
pituitaries with 10 µM 3-Me-HTRH reduced Gαq/11 density by 10%. 
 
 
Figure 24. 
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Figure 25. 
 
c. Hippocampal dentate gyrus slices superfused for 12 hours with 10 µM 
Free-Acid-TRH showed no significant change in Gαq/11 levels. 
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6. Effect of TRH on NMDA/DHPG-Damaged Superfused Hippocampal 
Slices 
 
Data in Figures 26, 27, 28 and 29 show that superfused slices, which were 
treated with 3-Me-HTRH for 15 hours after 30 minutes exposure to toxic NMDA and 
DHPG, showed significantly less death and damage than slices not treated with 3-Me-
HTRH. 
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Figure 26. 
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Figure 27. 
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Figure 28. 
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EFFECT OF 3M-HIS-TRH ON DHPG/NMDA CELL DAMAGE IN 
HIPPOCAMPAL NEURONAL CULTURE
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Figure 29. 
 
 
7.  Effect of TRH on Gαq/11 Levels in Superfused Hippocampal Slices and 
the Anterior Pituitary 
 
After superfusion, slices were homogenized and subjected to Western blotting 
with Gα standards. Blots were scanned and densities determined semi-quantitatively via 
image analysis. Slices superfused with 3-Me-HTRH or TRH showed a significant 
reduction in Gα compared to controls. Superfusion with Free-Acid-TRH showed no 
change. Similar results were seen with anterior pituitaries. 
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8. Effect of NMDA + DHPG on Cell Viability in Fetal Hippocampal 
Neurons 
 
To further investigate the effect of TRH on excitoxicity in the hippocampus, fetal 
hippocampal neurons were harvested (Appendix). Trypan blue exclusion analyses were 
performed on fetal hippocampal neurons that had been exposed to a combination of 
DHPG (5 µM, D5; 10 µM, D10; or 100 µM, D100) + NMDA (30 µM, N30) or N30 and 
D10 for 30 minutes, followed by 18 hours of culture in neurobasal medium. Exposure to 
a combination of D10/N30, D100/N30, and to N30 and D10 alone resulted in 
significantly less cell viability (58%, 20%, 65%, 92% versus untreated control P<0.05). 
Exposure to D5/N30 was not significant. C= untreated control. (Figure 30) 
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9. Effect of NMDA + DHPG on LDH Release from Fetal Hippocampal 
Neurons 
 
LDH release analyses were performed on media from fetal hippocampal neurons 
that had been exposed to a combination of DHPG (5 µM, D5; 10 µM, D10; or 100 µM, 
D100) + NMDA (30 µM, N30) or N30 and D10 for 30 min, followed by 18 hours of 
culture in neurobasal medium. Exposure to a combination of D10/N30, D100/N30, and to 
N30 and D10 alone resulted in significantly increased cell damage (119%, 128%, 130%, 
115% versus untreated control P<0.05). Exposure to D5/N30 significantly reduced cell 
damage (P<0.05). C= untreated control. (Figure 31) 
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10. Effect of TRH on Cell Viability in Fetal Hippocampal Neurons. 
Trypan blue exclusion analyses were performed on fetal hippocampal neurons 
that had been exposed to a combination of DHPG (10 µM, D10) + NMDA (30 µM, N30); 
D10 + N30 + 3-Me-HTRH (1 µM or 10 µM) for 30 minutes followed by 18 hours of 
culture with 3-Me-HTRH (1 µM, T1 or 10 µM, T10). Concurrent and continued 
treatment with TRH (10 µM but not 1 µM) resulted in significantly less neuronal death 
(12%, 54% versus control P<0.05), respectively. C = untreated control; D10/N30 = 
treated control. (Figure 32) 
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Figure 32. 
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11. Effect of TRH on LDH Release from Fetal Hippocampal Neurons 
LDH release assays were performed on media from fetal hippocampal on fetal 
hippocampal neurons that had been exposed to a combination of DHPG (10 µM, D10) + 
NMDA (30 µM, N30); D10 + N30 + 3-Me-HTRH (1 µM or 10 µM) for 30 minutes 
followed by 18 hours of culture with 3-Me-HTRH (1 µM, T1; or 10 µM, T10). 
Concurrent and continued treatment with TRH (10 µM but not 1 µM) resulted in 
significantly less cell damage (110%, 123% versus control P<0.05), respectively. C = 
untreated control; D10/N30 = treated control. (Figure 33) 
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VI. DISCUSSION 
Regarding the cell studies, pre-treatment of GH-3 and PC12 cells with 10 µM 
TRH 8 hours prior to 8 hours of 100 nM glutamate exposure significantly reduced cell 
death and cell damage as assessed by viable cell counts and LDH assays, respectively. 
Furthermore, concurrent treatment of GH-3 and PC12 cells with 10 µM TRH at 
the same time as toxic glutamate (100 nM) exposure (16 hours) significantly reduced cell 
death and cell damage as assessed by viable cell counts and LDH assay, respectively. 
Finally, in the cell study, it was shown that delayed treatment of GH-3 and PC12 
cells with 10 µM TRH 8 hours after 8 hours toxic exposure to glutamate (100 nM) 
significantly reduced cell death and cell damage as assessed by viable cell counts and 
LDH assay, respectively. 
Regarding the slice superfusion studies, the results show that prolonged exposure 
to TRH results in downregulation of Gα in the hippocampus. It is important to note that 
superfused hippocampal slices remain viable for up to 15 hours, as assessed by LDH 
release and caspase activity, as well as morphological analysis, and neither TRH nor 
selected analogues are toxic to hippocampal slices when superfused for 15 hours when 
assessed by LDH release. 
Levels of Gαq/11 were significantly and substantially lower in slices treated with 
either TRH or its high affinity analogue, 3-Me-HTRH. These data thus suggest that the 
neuroprotective role of TRH in part may involve heterologous receptor downregulation 
of metabotropic glutamate receptors. 
Regarding the neuron studies, concurrent and continued treatment of fetal 
hippocampal neurons with 10 µM 3Me-HTRH (a stable analogue of TRH) for 18 hours 
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can protect against toxic exposure to a combination of ionotropic + metabotropic 
glutamate agonists (10 µM DHPG + 30 µM NMDA) in vitro. 
The preliminary superfusion results with AChE-I indicate that phenserine 
superfusion reduces APP level in the hippocampal slice model, suggesting that the drug 
may inhibit the amyloidogenic pathway. Notably, levels of sAPP were unchanged in 
slices treated with TRH or its analogues, suggesting no effect of TRH on secretase 
activity. 
 
A. TRH and Glutamate Toxicity 
TRH modulates glutamate action by previously unknown mechanisms (Renaud 
and Martin, 1975); (Renaud, 1978); (Renaud et al., 1979). In GH-3 and PC-12 cells, the 
protective role of TRH may involve modulation of glutamate-mediated ionic and/or 
secondary events, even though these cells most likely express different TRH/glutamate 
receptor and glutamate transporter profiles. 
One mechanism of TRH protective action in hippocampal tissue may involve 
heterologous downregulation of the Gαq/11 subunit of the heterotrimeric G-protein as a 
modulator of glutamate overexcitability. 
TRH receptors (TRH-R1, R2) and group I glutamate receptors (mGluR1,5) are co-
localized on granule cells of the dentate gyrus, and are the only receptor subclass to share 
this same signaling cascade (Gαq/11). 
 Since the Gαq/11 component of the heterotrimeric G-protein is shared by both 
TRH and group I metabotropic glutamate receptors, receptor-mediated downregulation of 
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shared cellular G-protein subunits has been proposed as a mechanism for the 
development of sustained heterologous receptor desensitization (Milligan and Green, 
1997). 
 
B. Heterologous Receptor Downregulation as a Possible Mechanism of TRH 
Neuroprotection 
 
The protective action of TRH may involve heterologous downregulation of the 
Gαq/11 subunit of the heterotrimeric G-protein as a modulator of glutamate 
overexcitability. TRH has been shown to activate calcium efflux in GH-3 cells (Nelson 
and Hinkle, 1994); (Drummond et al., 1989). 
The role of group I metabotropic glutamate receptors in synaptic overexcitability 
may be described as follows. Pre-synaptic glutamate binds to group I receptors, resulting 
in inhibition of group II and group III receptors, which will further result in increased 
calcium influx and excess pre-synaptic glutamate release. Post-synaptically, this excess 
glutamate blocks group II and group III modulation of receptor-mediated calcium influx 
and potassium efflux, resulting in overexcitability. 
A proposed mechanism of TRH modulation of glutamate overexcitability is that 
the TRH receptor complex internalizes upon binding to TRH, thus resulting in a rapid 
removal of Gα from the plasma membrane. This is an initial heterologous downregulation 
of the α subunit of the heterotrimeric G-protein of group I glutamate receptors pre- and 
post-synaptically. This group I receptor downregulation (uncoupling) results in 
disinhibition (upregulation) of group II and group III glutamate receptors that block 
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calcium influx and function to modulate excess pre-synaptic glutamate release and post-
synaptic glutamate overexcitability. 
 
C. Potential Methods for Delivery of TRH to the Hippocampus 
 
One additional study performed during the preparation of this thesis involved the 
hypothesis that sustained-release TRH is protective against glutamate toxicity in GH-3 
cells. Poly(lactic) acid (PLA) TRH polyanhydride nanoparticles (TRH-NPs) were used 
that allow sustained release of known concentrations of TRH. PLA TRH-NP (2% TRH) 
were not toxic to the cultured GH-3 cells after 24 hours exposure, followed by 8 hrs 
maintenance in low serum media (LSM) prior to harvesting, as indicated by trypan blue 
exclusion (cell viability) and LDH analysis (cell damage). No difference in either cell 
viability or cell damage was detected in cells treated with blank-NPs or TRH-NPs, versus 
controls in which the GH-3 cells were maintained in LSM alone for 32 hours. 
Additionally, treating the GH-3 cells with TRH-NPs either for 24 hours before 8 
hours toxic glutamate exposure or for 24 hours after 8 hours glutamate exposure 
demonstrated (1) protection against cell damage, as indicated by LDH analysis; and (2) 
increased cell viability, as indicated by trypan blue exclusion, versus GH-3 cells exposed 
to glutamate alone. The protective effect of TRH-NPs against glutamate toxicity was 
more apparent when the cells were treated with the TRH-NPs before exposure to 
glutamate toxicity rather than when added after glutamate toxicity. 
Trypan blue exclusion analyses were performed on GH-3 cells that had been 
treated with TRH-loaded nanoparticles for 24 hours. M/M = control cells in low serum 
media (LSM) for 32 hours, NP/M= Cells treated with 2% TRH-loaded nanoparticles for 
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24 hours, followed by 8 hours of LSM; T/M = Cells treated with TRH 10 µM for 24 
hours, followed by LSM for 8 hours; BLANK/M = Cells treated with blank nanoparticles 
for 24 hours, followed by 8 hours in LSM. No apparent difference in cell viability was 
detected in cells treated with either TRH or TRH-loaded nanoparticles, vs. untreated 
control. (Figure 30) 
LDH release analyses were performed on media from GH-3 cells, which had been 
treated with TRH-loaded nanoparticles for 24 hours. M/M = control cells in low serum 
media (LSM) for 32 hours, NP/M= Cells treated with 2% TRH-loaded nanoparticles for 
24 hours, followed by 8 hours of LSM; T/M = Cells treated with TRH 10 µM for 24 
hours, followed by LSM for 8 hours; BLANK/M = Cells treated with blank nanoparticles 
for 24 hours, followed by 8 hours in LSM. No apparent difference in LDH release was 
detected in cells treated with either TRH or TRH-loaded nanoparticles, vs. untreated 
control. (Figure 31) 
Trypan blue exclusion analyses were performed on GH-3 cells that had been 
treated with TRH-loaded nanoparticles for 24 hours prior to 8 hours of glutamate toxicity. 
M/M = control cells in low serum media (LSM) for 32 hours, M/G = 24 hours of LSM 
followed by 8 hours of 100 nM glutamate exposure; NP/G= Cells treated with 2% TRH-
loaded nanoparticles for 24 hours, followed by 8 hours of 100 nM glutamate exposure; 
T/G = Cells treated with TRH 10 µM for 24 hours, followed by 8 hours of 100 nM 
glutamate exposure. Cell viability was greater in cells pre-treated with either TRH or 
TRH-loaded nanoparticles prior to glutamate toxicity, vs. cells exposed to glutamate 
alone. (Figure 32) 
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LDH release analyses were performed on media from GH-3 cells that had been 
treated with TRH-loaded nanoparticles for 24 hours prior to 8 hours of glutamate toxicity. 
M/M = control cells in low serum media (LSM) for 32 hours, M/G = 24 hours of LSM 
followed by 8 hours of 100 nM glutamate exposure; NP/G= Cells treated with 2% TRH-
loaded nanoparticles for 24 hours, followed by 8 hours of 100 nM glutamate exposure; 
T/G = Cells treated with TRH 10 µM for 24 hours, followed by 8 hours of 100 nM 
glutamate exposure. LDH release was lower in cells pre-treated with either TRH or TRH-
loaded nanoparticles prior to glutamate toxicity, vs. cells exposed to glutamate alone. 
(Figure 33) 
Trypan blue exclusion analyses were performed on GH-3 cells, which had been 
exposed to 8 hours of glutamate toxicity prior to 24 hours of treatment with TRH-loaded 
nanoparticles. M/M = control cells in low serum media (LSM) for 32 hours, M/G = 24 
hours of LSM followed by 8 hours of 100 nM glutamate exposure; G/NP= Cells exposed 
to 8 hours of 100 nM glutamate exposure followed by treatment with 2% TRH-loaded 
nanoparticles for 24 hours; G/T = Cells exposed to 8 hours of 100 nM glutamate 
exposure followed by treatment with TRH 10 µM for 24 hours. Cell viability was greater 
in cells treated with either TRH or TRH-loaded nanoparticles after glutamate toxicity vs. 
cells exposed to glutamate alone. (Figure 34) 
LDH release analyses were performed on media from GH-3 cells, which had been 
exposed to 8 hours of glutamate toxicity prior to 24 hours of treatment with TRH-loaded 
nanoparticles. M/M = control cells in low serum media (LSM) for 32 hours, M/G = 24 
hours of LSM followed by 8 hours of 100 nM glutamate exposure; G/NP= Cells exposed 
to 8 hours of 100 nM glutamate exposure followed by treatment with 2% TRH-loaded 
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nanoparticles for 24 hours; G/T = Cells exposed to 8 hours of 100 nM glutamate 
exposure followed by treatment with TRH 10 µM for 24 hours. LDH release was lower 
in cells treated with either TRH or TRH-loaded nanoparticles after glutamate toxicity vs. 
cells exposed to glutamate alone. (Figure 35) 
These results should hasten the development of polyanhydride-based sustained-
release carriers for TRH as well as other neuropeptides in vitro.  
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VII. SUMMARY 
The results of the cell study showed that TRH is protective against glutamate 
toxicity when added before, during, or after the toxic insult. This is important when one 
considers treatment for excitotoxic events such as epilepsy, stroke, and trauma. 
The slice superfusion study increased the complexity of the environment in which 
the neuroprotective effect of TRH against excitotoxicty was investigated. This also 
allowed us to determine a possible mechanism for the neuroprotective effect of TRH; i.e., 
TRH modulates the effect of glutamate via heterologous receptor downregulation, as 
shown by the downregulation of Gαq/11 when TRH or its stable analog, 3-Me-HTRH, is 
added during toxic exposure of hippocampal dentate gyri slices to NMDA + DHPG. 
To further this investigation, the neuroprotecive effect of TRH against excitatory 
amino acid-induced toxicity in fetal neurons was also investigated. 
The neuronal study results show the dose-dependent toxicity of 
dihydroxyphenylglycine (DHPG) on cell death and membrane damage in neurons when 
added either alone or in combination with N-methyl-D-aspartate (NMDA). Exposure to 
30 µM NMDA or 10 µM DHPG, or to 10 µM or 100 µM DHPG + 30 µM NMDA 
resulted in significantly less cell viability and significantly more cell damage than 
exposure to 5 µM DHPG + 30 µM NMDA.  The 5 µM DHPG appeared to block the 
NMDA effect. 
Notably, the results of the neuronal study show that concurrent and continued 
treatment with 10 µM 3Me-HTRH (a stable analogue of TRH) resulted in significantly 
less neuronal death and damage when added to a toxic dose of 10 µM DHPG + 30 µM 
NMDA.  Treatment with 1 µM 3Me-HTRH did not have a significant effect. 
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VIII. CONCLUSION 
 
These results support and extend our ongoing research, as well as that of others 
showing a neuroprotective role for TRH against glutamate neurotoxicity (Jaworska-Feil 
et al., 2001). 
This work has indicated that one mechanism of TRH protective action in 
hippocampal tissue may involve heterologous downregulation of the Gαq/11 subunit of the 
heterotrimeric G-protein as a modulator of glutamate overexcitability (Milligan and 
Green, 1997); (Kim et al., 1994); (Pesanova et al., 1999). TRH receptors (TRH-R1) and 
group I glutamate receptors (mGluR1,5) are colocalized in granule cells of the dentate 
gyrus and share this same signaling cascade (Gαq/11) (Blumcke et al., 2000); (Heuer et al., 
2000). 
A role for group I metabotropic glutamate receptors in synaptic overexcitability 
involves pre-synaptic glutamate binding to group I receptors, resulting in indirect 
inhibition of both groups II and III metabotropic receptors. This causes increased calcium 
influx and excess pre-synaptic glutamate release. Post-synaptically, excess group I 
activation blocks groups II and III inhibition of receptor-mediated calcium influx and 
potassium efflux. PKC-mediated phosphorylation of NMDA receptors reduces the Mg++ 
block resulting in overexcitability (Mukhin et al., 1997); (Chen et al., 1999). 
A proposed mechanism of TRH protection against excitatory amino-acid-induced 
excitotoxicity involves the TRH receptor complex internalizing upon binding, resulting in 
rapid Gαq/11 removal from the plasma membrane initially, and heterologous 
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downregulation of the A subunit of the heterotrimeric G-protein of group I metabotropic 
glutamate receptors pre- and post-synaptically (Svoboda et al., 1996). 
The data suggest that TRH may be a selective modulator of glutamate-induced 
toxicity. This is relevant to TRH neuropeptide treatment in post-traumatic and other 
neurodegenerative events, such as dementia (Alzheimer’s disease), seizures, and stroke. 
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IX. FUTURE DIRECTIONS 
 
A. Selectivity of the TRH Effect on Other G-Protein Subunits 
Future studies should be developed to determine whether the neuroprotective 
effect of TRH extends to other G-protein coupled receptors, in which Gi, Go, and Gs 
levels will be examined via Western blotting techniques in slice and neuronal systems. 
 
B. Effect of TRH on Muscarinic Cholinergic Receptors in the Hippocampus 
The effect of TRH on metabotropic acetylcholine receptors in the hippocampus 
should also be examined, as the neuroprotective effect of TRH may not be limited to 
heterologous receptor desensitization of metabotropic glutamate receptors. This has 
implications with treatment of Alzheimer’s disease. 
 
C. Effect of TRH on Tau Protein in the Hippocampus 
The effect of exposure to TRH on tau protein development in hippocampal 
neurons should also be examined, as TRH may prove to be neuroprotective against the 
development or progression of Alzheimer’s disease, through mechanisms as yet 
undiscovered. 
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X. APPENDICES 
 
A. Protocol for Hippocampal/Dentate Gyri Slice Superfusion 
 
1. Prepare SUPERFUSION Buffers 24 hours prior to Experiment, as follows: 
 
(a) KRB STOCK A (Make in Duplicate, 2 liters, for each 
experiment) 
 
NaH2PO4-H2O  0.154 g 
NaCl    5.747 g 
NaHCO3   1.867 g 
Dextrose (10mM)  1.8 g 
Na2HPO4   0.142 g 
 
qs to 1 liter w/H2O 
pH to 7.4 
 
(b) KRB STOCK B 
NaCl    2.718 g 
KCl (3.5 mM)   0.26 g 
BSA    0.1 g 
CaCl    0.147 g (LOW CALCIUM @ 1.0 mM) 
    0.368 g (NORMAL CALCIUM @ 2.5 mM) 
 
qs to 100 ml w/H2O 
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2. Combine Stock A plus Stock B (low calcium) 2 hours prior to Experiment. 
Warm to room temperature in the SUPERFUSION Room for 1 hour. 
Reconfirm pH at 7.4. Oxygenate in 37°C water bath for 1 hour. 
 
3. Combine Stock A plus Stock B (normal calcium) to make final volume of 
2.2 liters normal calcium Buffer. Warm to room temperature and 
reconfirm pH at 7.4 prior to SUPERFUSION. Oxygenate in 37°C water 
bath for 1 hour prior to SUPERFUSION with normal calcium buffer. 
 
4. Obtain beasts from LARC. Cover cart with cloth and transport animals to 
just outside the door of MS510.  Only take 1 animal at a time into the 
Decapitation Room. 
 
5. Weigh rat. Decapitate and remove brain. Place immediately in ice cold 
0.9% NaCl. 
 
6. Subdissect hippocampi/dentate gyri in accordance with dissection protocol 
in the SUPERFUSION Room under magnification, using an aluminum 
tray with a dry ice layer covered with regular ice (1:9) to prevent freezing 
and/or thawing. Keep the tissue wet with ice cold 0.9% NaCl at all times. 
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7. Once the desired tissue is obtained, slice to 500 µM thickness under 
magnification. Blot dry and weigh. Record DG/HIPP # by weight and 
date. Repeat for each hippocampus/dentate gyrus. 
 
8. Place the tissue, by either animal R/L side or randomized sections, into 
SUPERFUSION wells. Superfuse with oxygenated low calcium buffer @ 
0.5 ml/min for 2 hours. Keep oxygenation going throughout entire 
procedure. 
 
9. After 2 hours, obtain 1 ml effluent from each well for LDH assay (T-0). 
Freeze at -20°C until assay is performed. 
 
10. Without disrupting wells, switch to SUPERFUSION with normal calcium 
buffer with drug/dose of choice in wells 2 and 4, and normal calcium 
buffer with no drug (untreated controls) in wells 1 and 3. 
 
11. Collect 1 ml effluent from each well at beginning (T-0), and every 4 hours 
until the end of the experiment (T endpoint). Label each tube with 
date/time of collection. Keep TOTAL effluent in labeled bottles. Place 
effluents into refrigerator for LDH/protein analyses. At endpoint, remove 
the superfused tissue from the wells, place in individually labeled 2ml 
Eppendorf tubes, and freeze at -70°C until ready to analyze. 
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12. When ready to analyze, remove the tissue from -70°C and place the 
superfused tissue in 500 µl ice cold IP Buffer (protease inhibitor). 
Homogenize with polytron homogenizer at 50% speed for 10 seconds. 
Cold centrifuge for 15 minutes. Separate tissue from effluent. Freeze 
pellets at -70°C for future analyses. 
 
13. Perform Protein Estimation of cell lysate via Lowry Method. Calculate 
amount protein/wet weight of original tissue. Aliquot 15-30 µg protein 
from each sample. Add water and 4X Sample Buffer to obtain 40-50 µl 
total for each sample. Boil for 5 minutes. 
 
14. Perform Lactic Dehydrogenase (LDH) Assay on cell lysate, using SIGMA 
LDH Assay kit. Record results. 
 
15. Perform PAGE in 12% agarose gel. Run gel at 200V for 48 minutes. 
Perform western blot transfer to nitrocellulose membrane via running in 
transfer buffer at 110V for 60 minutes. Stain with Ponceau and visualize 
with acetic acid to verify serum protein transfer has occurred in equal 
amounts per well. Photograph blot in GDS system. Wash off Ponceau with 
TBST buffer for 10 minutes X3. 
 
16. Block nonspecific binding with 3% gelatin incubation for 1-2 hours. Wash 
with TBST for 10 minutes X3. 
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17. Probe overnight with primary antibody of choice. Keep antibody and rinse 
blot with TBST for 10 minutes X3. 
 
18. Hybridize with secondary antibody for 1-2 hours. Keep antibody and rinse 
blot with TBS buffer for 10 minutes X3. 
 
19. Add biotinylated avidin (VECTASTAIN kit) for 1 hour. Rinse blot with 
TBS buffer for 10 minutes X3. 
 
20. Develop blot with horseradish peroxidase. 
  
21. Perform densitometric analysis of Western Blots with Scion Image 
program. Save blot in water or plastic-sealed bag for future probing. 
 
22. Plot results on Excel. Calculate percent change of treated versus untreated 
cell lysates for protein of choice. 
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B. IMMUNOHISTOCHEMISTRY PROTOCOL (MORPHOLOGICAL 
ANALYSIS) 
 
N.B.  Use gelatin-coated slides for frozen sections. 
 Dilute antibody (Ab) in PBS. (e.g. Sheep kit: 1.5% Normal Serum + 0.3% Tx-
100) 
 
Day 1: Frozen sections (cryostat) 
 
Day 2: Immunohistochemistry Staining Protocol – Part 1 
 
1. BLOCK 
In graduated cylinder: 
90 ml PBS 
10 ml H2O2 
 
2. Add PBS/ H2O2 solution to slides 
-rock for 10 minutes 
-air bubbles will form 
 
3. WASH 3x (5-10 min each) with PBS 
-get rid of air bubbles 
 
4. Circle tissue with Liquid Blocker (a liquid-repellant slide marker pen for 
staining) 
-dry for 5 minutes 
 
 
137 
 
5. Place wet paper towels in the bottom of the slide box, for humidification. 
 
6. Incubate with 1° Ab (inside circle of liquid repellant) O/N. 
(N.B. Cover the slide box.) 
 
Day 3: Immunohistochemistry Staining Protocol – Part 2 
 
7. RINSE 3x for 10 minutes with PBS (0.1 µM) 
 
8. 2° Ab (1:200) for 1 hour in TBS 
 
9. RINSE 3x for 10 minutes with PBS 
 
10. RINSE 2x for 10 minutes with TBS 
 
11. Add ABC (2 drops A + 2 drops B in 5 ml TBS) and incubate for 1 hour. 
 
12. Rinse 3x for 10 minutes with TBS. 
 
13. Develop with DAB. (100 µl DAB + 900 µl Buffer) 
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C. FETAL NEURON HARVEST TECHNIQUE 
 
1. Fetal rats were harvested from pregnant Sprague-Dawley dams at 
embryonic day 17, and placed in sterile Hank’s buffered medium with 
pyruvate at pH 7.4. 
 
2. Heads were removed, and then isolated under a dissecting scope on a 
black wax-coated sterile Petri dish (for ease of viewing). 
 
3. Specimens were pinned to enable dissection from a superior view. The 
dura mater was peeled away, and the underlying arachnoid and pia mater 
were punctured and peeled away using sterile scissors and forceps. 
 
4. The olfactory bulbs and cerebellum were removed, and the remaining 
cerebral lobes were bisected mid-sagittally.  The midbrain was removed 
and the hippocampi were isolated. 
 
5. Whole hippocampi were centrifuged for 2 minutes at low speed and the 
Hank’s media was aspirated off the remaining pellet under a hood to 
maintain sterile conditions. 
 
6. Neurobasal medium (10 ml) containing B27 (serum-free medium), L-
Glutamine and Pen-Strep (with BDNF) was added to the pellet. 
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7. The hippocampal pellet was triturated until the mixture was cloudy and 
homogeneous. 
 
8. Cells (106) were cultured in 2 ml neurobasal serum-free medium in eight-
well dishes coated with 0.2 mg/ml poly-D-lysine as described (by Brewer, 
et. al., 1998). Neurons were maintained in a 5% CO2 incubator at 37°C for 
14 days, with media changes every 2 days. 
 
9. Neurons were exposed for 30 minutes to the following:  media control; 
DHPG (10 µM); NMDA (30 µM); DHPG (5, 10, or 100 µM) + NMDA 
(30 µM); and DHPG (10 µM) + NMDA (30 µM) + 3-Me-HTRH (1 µM 
OR 10 µM) in neurobasal medium. 
 
10. This procedure was followed by 18 hours of treatment with 3-Me-HTRH 
(1 µM OR 10 µM) in neurobasal medium. 
 
11. After 18 hours, 50 µl aliquots of conditioned media were collected for 
lactic dehydrogenase (LDH) analysis by a colorimetric tetrazolium dye 
method (Sigma) to assess cell membrane integrity.  Cells were harvested, 
and cell counts were performed via trypan blue exclusion to determine cell 
viability. 
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